Global Vaccine Particulate Adjuvants Supply, Demand and Key Producers, 2026-2032
The global Vaccine Particulate Adjuvants market size is expected to reach $ 1520 million by 2032, rising at a market growth of 3.3% CAGR during the forecast period (2026-2032).
Vaccine Particulate Adjuvants are a class of adjuvants or adjuvant systems that exist as particles, colloids, vesicles, complexes, or other discrete micro- and nanostructures and are used to enhance vaccine immunogenicity, improve antigen delivery, and shape the quality of immune responses. They may appear as milky or translucent suspensions, colloidal dispersions, lyophilized powders, wet gels, or reconstituted particulate systems. Structurally, they commonly consist of inorganic salt particles, lipid bilayer vesicles, saponin-lipid complexes, virosomes, polymeric micro- or nanoparticles, or other biomimetic particulate carriers. Typical components include aluminum hydroxide, aluminum phosphate, cholesterol, phospholipids, saponins, monophosphoryl lipid A analogs, biodegradable polymers, and surface-functional excipients. Their mode of action is not limited to simple immune stimulation; rather, they adsorb, entrap, or co-deliver antigens in a particulate form that is more efficiently taken up by antigen-presenting cells. By tuning particle size, surface charge, rigidity, and interfacial chemistry, they promote cell recruitment at the administration site, lymph node trafficking, dendritic cell activation, and coordinated humoral and cellular immunity. Main categories include aluminum-salt particulates, liposomal adjuvants, virosomal adjuvants, ISCOM/ISCOMATRIX-type adjuvants, polymeric particle adjuvants, and other inorganic or biomimetic particulate adjuvants. Their major applications are in recombinant protein vaccines, subunit vaccines, conjugate vaccines, selected inactivated vaccines, therapeutic cancer vaccines, and veterinary vaccines.
Growth opportunities for Vaccine Particulate Adjuvants are primarily driven by changes in vaccine antigen platforms. Recombinant protein, subunit, conjugate, and many therapeutic vaccines are inherently less immunogenic and therefore more dependent on efficient delivery and immune amplification. Particulate systems are well positioned because they function both as carriers and as immune modulators. Mature aluminum-based systems will continue to provide the bulk of demand, while liposomes, ISCOM/Matrix-M, nano-alum, and polymeric particles are expected to gain share in elderly populations, immunologically weaker populations, and indications requiring stronger Th1 or cellular responses. The real opportunity for suppliers is not merely whether an adjuvant is present, but whether they can build scalable, stable, globally registrable adjuvant platforms compatible with new antigen formats. As RSV, malaria, shingles, broad influenza, therapeutic cancer vaccines, and next-generation veterinary vaccines advance, particulate systems that enable antigen sparing, durable immunity, cold-chain practicality, and differentiated protection profiles should continue to gain commercial importance.
The main restraints in this market are not conceptual novelty but scale-up, raw-material consistency, and regulatory comparability. Particulate adjuvants are highly sensitive to particle-size distribution, surface charge, adsorption capacity, reconstitution behavior, stability windows, and batch-to-batch reproducibility. Once a product moves from laboratory work into commercial manufacturing, the allowable process window narrows sharply. Aluminum salts are mature but offer limited differentiation, whereas liposomal and saponin-complex particles can provide stronger performance but demand tighter control of raw material purity, loading strategy, freeze-thaw stability, analytical methods, and supply-chain security. Critical inputs such as QS-21, MPL-like molecules, specialty lipids, and high-purity phospholipids may also be constrained by plant sourcing, licensing, purification routes, and global production footprint. For investors and industrial analysts, the central risk is to confuse ?works in research? with ?can be manufactured reproducibly at scale,? or to mistake a captive in-house vaccine adjuvant platform for an externally scalable commercial adjuvant business. Competition will therefore increasingly center on CMC, regulatory pathways, intellectual property, and manufacturing scale rather than preclinical efficacy alone.
Downstream demand is showing three clear trends. First, demand is expanding from traditional pediatric immunization into vaccines for older adults, maternal vaccines, cancer immunotherapy, and vaccines for highly pathogenic emerging infections, increasing preference for particulate platforms that can support both antibody and cellular immunity. Second, customers are moving away from simple procurement of standard alum and toward adjuvant-system solutions, meaning they increasingly seek not just a raw material but a combined package of formulation know-how, process support, analytics, and licensing. Third, veterinary vaccines remain a stable and meaningful demand base, especially in multivalent products, mucosal immunization, and long-duration protection, where polymeric, gel-based, and hybrid particulate systems retain strong relevance. Overall, the market is unlikely to reward the strongest inflammatory signal alone; instead, future purchasing will favor a balanced combination of breadth of protection, tolerability, dose sparing, elderly immune performance, mucosal potential, and global supply reliability.
This report studies the global Vaccine Particulate Adjuvants production, demand, key manufacturers, and key regions.
This report is a detailed and comprehensive analysis of the world market for Vaccine Particulate Adjuvants and provides market size (US$ million) and Year-over-Year (YoY) Growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of Vaccine Particulate Adjuvants that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Vaccine Particulate Adjuvants total production and demand, 2021-2032, (K Units)
Global Vaccine Particulate Adjuvants total production value, 2021-2032, (USD Million)
Global Vaccine Particulate Adjuvants production by region & country, production, value, CAGR, 2021-2032, (USD Million) & (K Units), (based on production site)
Global Vaccine Particulate Adjuvants consumption by region & country, CAGR, 2021-2032 & (K Units)
U.S. VS China: Vaccine Particulate Adjuvants domestic production, consumption, key domestic manufacturers and share
Global Vaccine Particulate Adjuvants production by manufacturer, production, price, value and market share 2021-2026, (USD Million) & (K Units)
Global Vaccine Particulate Adjuvants production by Type, production, value, CAGR, 2021-2032, (USD Million) & (K Units)
Global Vaccine Particulate Adjuvants production by Application, production, value, CAGR, 2021-2032, (USD Million) & (K Units)
This report profiles key players in the global Vaccine Particulate Adjuvants market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include GSK, Merck, Sanofi, Croda, Novavax, SPI Pharma, CSL, Serum Institute of India, Bharat Biotech, Biological E, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Vaccine Particulate Adjuvants market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), volume (production, consumption) & (K Units) and average price (US$/Unit) by manufacturer, by Type, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.
Global Vaccine Particulate Adjuvants Market, By Region:
1. How big is the global Vaccine Particulate Adjuvants market?
2. What is the demand of the global Vaccine Particulate Adjuvants market?
3. What is the year over year growth of the global Vaccine Particulate Adjuvants market?
4. What is the production and production value of the global Vaccine Particulate Adjuvants market?
5. Who are the key producers in the global Vaccine Particulate Adjuvants market?
6. What are the growth factors driving the market demand?
Vaccine Particulate Adjuvants are a class of adjuvants or adjuvant systems that exist as particles, colloids, vesicles, complexes, or other discrete micro- and nanostructures and are used to enhance vaccine immunogenicity, improve antigen delivery, and shape the quality of immune responses. They may appear as milky or translucent suspensions, colloidal dispersions, lyophilized powders, wet gels, or reconstituted particulate systems. Structurally, they commonly consist of inorganic salt particles, lipid bilayer vesicles, saponin-lipid complexes, virosomes, polymeric micro- or nanoparticles, or other biomimetic particulate carriers. Typical components include aluminum hydroxide, aluminum phosphate, cholesterol, phospholipids, saponins, monophosphoryl lipid A analogs, biodegradable polymers, and surface-functional excipients. Their mode of action is not limited to simple immune stimulation; rather, they adsorb, entrap, or co-deliver antigens in a particulate form that is more efficiently taken up by antigen-presenting cells. By tuning particle size, surface charge, rigidity, and interfacial chemistry, they promote cell recruitment at the administration site, lymph node trafficking, dendritic cell activation, and coordinated humoral and cellular immunity. Main categories include aluminum-salt particulates, liposomal adjuvants, virosomal adjuvants, ISCOM/ISCOMATRIX-type adjuvants, polymeric particle adjuvants, and other inorganic or biomimetic particulate adjuvants. Their major applications are in recombinant protein vaccines, subunit vaccines, conjugate vaccines, selected inactivated vaccines, therapeutic cancer vaccines, and veterinary vaccines.
Growth opportunities for Vaccine Particulate Adjuvants are primarily driven by changes in vaccine antigen platforms. Recombinant protein, subunit, conjugate, and many therapeutic vaccines are inherently less immunogenic and therefore more dependent on efficient delivery and immune amplification. Particulate systems are well positioned because they function both as carriers and as immune modulators. Mature aluminum-based systems will continue to provide the bulk of demand, while liposomes, ISCOM/Matrix-M, nano-alum, and polymeric particles are expected to gain share in elderly populations, immunologically weaker populations, and indications requiring stronger Th1 or cellular responses. The real opportunity for suppliers is not merely whether an adjuvant is present, but whether they can build scalable, stable, globally registrable adjuvant platforms compatible with new antigen formats. As RSV, malaria, shingles, broad influenza, therapeutic cancer vaccines, and next-generation veterinary vaccines advance, particulate systems that enable antigen sparing, durable immunity, cold-chain practicality, and differentiated protection profiles should continue to gain commercial importance.
The main restraints in this market are not conceptual novelty but scale-up, raw-material consistency, and regulatory comparability. Particulate adjuvants are highly sensitive to particle-size distribution, surface charge, adsorption capacity, reconstitution behavior, stability windows, and batch-to-batch reproducibility. Once a product moves from laboratory work into commercial manufacturing, the allowable process window narrows sharply. Aluminum salts are mature but offer limited differentiation, whereas liposomal and saponin-complex particles can provide stronger performance but demand tighter control of raw material purity, loading strategy, freeze-thaw stability, analytical methods, and supply-chain security. Critical inputs such as QS-21, MPL-like molecules, specialty lipids, and high-purity phospholipids may also be constrained by plant sourcing, licensing, purification routes, and global production footprint. For investors and industrial analysts, the central risk is to confuse ?works in research? with ?can be manufactured reproducibly at scale,? or to mistake a captive in-house vaccine adjuvant platform for an externally scalable commercial adjuvant business. Competition will therefore increasingly center on CMC, regulatory pathways, intellectual property, and manufacturing scale rather than preclinical efficacy alone.
Downstream demand is showing three clear trends. First, demand is expanding from traditional pediatric immunization into vaccines for older adults, maternal vaccines, cancer immunotherapy, and vaccines for highly pathogenic emerging infections, increasing preference for particulate platforms that can support both antibody and cellular immunity. Second, customers are moving away from simple procurement of standard alum and toward adjuvant-system solutions, meaning they increasingly seek not just a raw material but a combined package of formulation know-how, process support, analytics, and licensing. Third, veterinary vaccines remain a stable and meaningful demand base, especially in multivalent products, mucosal immunization, and long-duration protection, where polymeric, gel-based, and hybrid particulate systems retain strong relevance. Overall, the market is unlikely to reward the strongest inflammatory signal alone; instead, future purchasing will favor a balanced combination of breadth of protection, tolerability, dose sparing, elderly immune performance, mucosal potential, and global supply reliability.
This report studies the global Vaccine Particulate Adjuvants production, demand, key manufacturers, and key regions.
This report is a detailed and comprehensive analysis of the world market for Vaccine Particulate Adjuvants and provides market size (US$ million) and Year-over-Year (YoY) Growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of Vaccine Particulate Adjuvants that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Vaccine Particulate Adjuvants total production and demand, 2021-2032, (K Units)
Global Vaccine Particulate Adjuvants total production value, 2021-2032, (USD Million)
Global Vaccine Particulate Adjuvants production by region & country, production, value, CAGR, 2021-2032, (USD Million) & (K Units), (based on production site)
Global Vaccine Particulate Adjuvants consumption by region & country, CAGR, 2021-2032 & (K Units)
U.S. VS China: Vaccine Particulate Adjuvants domestic production, consumption, key domestic manufacturers and share
Global Vaccine Particulate Adjuvants production by manufacturer, production, price, value and market share 2021-2026, (USD Million) & (K Units)
Global Vaccine Particulate Adjuvants production by Type, production, value, CAGR, 2021-2032, (USD Million) & (K Units)
Global Vaccine Particulate Adjuvants production by Application, production, value, CAGR, 2021-2032, (USD Million) & (K Units)
This report profiles key players in the global Vaccine Particulate Adjuvants market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include GSK, Merck, Sanofi, Croda, Novavax, SPI Pharma, CSL, Serum Institute of India, Bharat Biotech, Biological E, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Vaccine Particulate Adjuvants market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), volume (production, consumption) & (K Units) and average price (US$/Unit) by manufacturer, by Type, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.
Global Vaccine Particulate Adjuvants Market, By Region:
- United States
- China
- Europe
- Japan
- South Korea
- ASEAN
- India
- Rest of World
- Oral
- Subcutaneous
- Intranasal
- Intramuscular
- Intradermal
- Others
- Mineral gel / precipitated particles
- Liposomal vesicles
- Virosomal vesicles
- Saponin nanoparticle / ISCOM-type complexes
- Polymeric micro- or nanoparticles
- Others
- Aluminum salt-based particulate adjuvants
- Phospholipid-based particulate adjuvants
- Saponin-based particulate adjuvants
- Polymer-based particulate adjuvants
- Virus-membrane / virosome-based particulate adjuvants
- Hybrid particulate systems
- Others
- Surface-adsorbed particulate systems
- Encapsulated particulate systems
- Co-assembled particulate systems
- Admixture particulate systems
- Others
- Infectious Diseases
- Cancer
- Others
- GSK
- Merck
- Sanofi
- Croda
- Novavax
- SPI Pharma
- CSL
- Serum Institute of India
- Bharat Biotech
- Biological E
- Panacea Biotec
- Valneva
- SEPPIC
- Phibro Animal Health
- Aurorium
- Agenus
- InvivoGen
- OZ Biosciences
- Vaxine
- Adjuvatis
- Desert King
- Sinovac
- China National Biotec Group
- Walvax
- Anhui Zhifei Longcom
1. How big is the global Vaccine Particulate Adjuvants market?
2. What is the demand of the global Vaccine Particulate Adjuvants market?
3. What is the year over year growth of the global Vaccine Particulate Adjuvants market?
4. What is the production and production value of the global Vaccine Particulate Adjuvants market?
5. Who are the key producers in the global Vaccine Particulate Adjuvants market?
6. What are the growth factors driving the market demand?
1 SUPPLY SUMMARY
1.1 Vaccine Particulate Adjuvants Introduction
1.2 World Vaccine Particulate Adjuvants Supply & Forecast
1.2.1 World Vaccine Particulate Adjuvants Production Value (2021 & 2025 & 2032)
1.2.2 World Vaccine Particulate Adjuvants Production (2021-2032)
1.2.3 World Vaccine Particulate Adjuvants Pricing Trends (2021-2032)
1.3 World Vaccine Particulate Adjuvants Production by Region (Based on Production Site)
1.3.1 World Vaccine Particulate Adjuvants Production Value by Region (2021-2032)
1.3.2 World Vaccine Particulate Adjuvants Production by Region (2021-2032)
1.3.3 World Vaccine Particulate Adjuvants Average Price by Region (2021-2032)
1.3.4 Europe Vaccine Particulate Adjuvants Production (2021-2032)
1.3.5 North America Vaccine Particulate Adjuvants Production (2021-2032)
1.3.6 China Vaccine Particulate Adjuvants Production (2021-2032)
1.3.7 South Korea Vaccine Particulate Adjuvants Production (2021-2032)
1.3.8 India Vaccine Particulate Adjuvants Production (2021-2032)
1.3.9 Australia Vaccine Particulate Adjuvants Production (2021-2032)
1.4 Market Drivers, Restraints and Trends
1.4.1 Vaccine Particulate Adjuvants Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Vaccine Particulate Adjuvants Major Market Trends
2 DEMAND SUMMARY
2.1 World Vaccine Particulate Adjuvants Demand (2021-2032)
2.2 World Vaccine Particulate Adjuvants Consumption by Region
2.2.1 World Vaccine Particulate Adjuvants Consumption by Region (2021-2026)
2.2.2 World Vaccine Particulate Adjuvants Consumption Forecast by Region (2027-2032)
2.3 United States Vaccine Particulate Adjuvants Consumption (2021-2032)
2.4 China Vaccine Particulate Adjuvants Consumption (2021-2032)
2.5 Europe Vaccine Particulate Adjuvants Consumption (2021-2032)
2.6 Japan Vaccine Particulate Adjuvants Consumption (2021-2032)
2.7 South Korea Vaccine Particulate Adjuvants Consumption (2021-2032)
2.8 ASEAN Vaccine Particulate Adjuvants Consumption (2021-2032)
2.9 India Vaccine Particulate Adjuvants Consumption (2021-2032)
3 WORLD MANUFACTURERS COMPETITIVE ANALYSIS
3.1 World Vaccine Particulate Adjuvants Production Value by Manufacturer (2021-2026)
3.2 World Vaccine Particulate Adjuvants Production by Manufacturer (2021-2026)
3.3 World Vaccine Particulate Adjuvants Average Price by Manufacturer (2021-2026)
3.4 Vaccine Particulate Adjuvants Company Evaluation Quadrant
3.5 Industry Rank and Concentration Rate (CR)
3.5.1 Global Vaccine Particulate Adjuvants Industry Rank of Major Manufacturers
3.5.2 Global Concentration Ratios (CR4) for Vaccine Particulate Adjuvants in 2025
3.5.3 Global Concentration Ratios (CR8) for Vaccine Particulate Adjuvants in 2025
3.6 Vaccine Particulate Adjuvants Market: Overall Company Footprint Analysis
3.6.1 Vaccine Particulate Adjuvants Market: Region Footprint
3.6.2 Vaccine Particulate Adjuvants Market: Company Product Type Footprint
3.6.3 Vaccine Particulate Adjuvants Market: Company Product Application Footprint
3.7 Competitive Environment
3.7.1 Historical Structure of the Industry
3.7.2 Barriers of Market Entry
3.7.3 Factors of Competition
3.8 New Entrant and Capacity Expansion Plans
3.9 Mergers, Acquisition, Agreements, and Collaborations
4 UNITED STATES VS CHINA VS REST OF THE WORLD
4.1 United States VS China: Vaccine Particulate Adjuvants Production Value Comparison
4.1.1 United States VS China: Vaccine Particulate Adjuvants Production Value Comparison (2021 & 2025 & 2032)
4.1.2 United States VS China: Vaccine Particulate Adjuvants Production Value Market Share Comparison (2021 & 2025 & 2032)
4.2 United States VS China: Vaccine Particulate Adjuvants Production Comparison
4.2.1 United States VS China: Vaccine Particulate Adjuvants Production Comparison (2021 & 2025 & 2032)
4.2.2 United States VS China: Vaccine Particulate Adjuvants Production Market Share Comparison (2021 & 2025 & 2032)
4.3 United States VS China: Vaccine Particulate Adjuvants Consumption Comparison
4.3.1 United States VS China: Vaccine Particulate Adjuvants Consumption Comparison (2021 & 2025 & 2032)
4.3.2 United States VS China: Vaccine Particulate Adjuvants Consumption Market Share Comparison (2021 & 2025 & 2032)
4.4 United States Based Vaccine Particulate Adjuvants Manufacturers and Market Share, 2021-2026
4.4.1 United States Based Vaccine Particulate Adjuvants Manufacturers, Headquarters and Production Site (States, Country)
4.4.2 United States Based Manufacturers Vaccine Particulate Adjuvants Production Value (2021-2026)
4.4.3 United States Based Manufacturers Vaccine Particulate Adjuvants Production (2021-2026)
4.5 China Based Vaccine Particulate Adjuvants Manufacturers and Market Share
4.5.1 China Based Vaccine Particulate Adjuvants Manufacturers, Headquarters and Production Site (Province, Country)
4.5.2 China Based Manufacturers Vaccine Particulate Adjuvants Production Value (2021-2026)
4.5.3 China Based Manufacturers Vaccine Particulate Adjuvants Production (2021-2026)
4.6 Rest of World Based Vaccine Particulate Adjuvants Manufacturers and Market Share, 2021-2026
4.6.1 Rest of World Based Vaccine Particulate Adjuvants Manufacturers, Headquarters and Production Site (State, Country)
4.6.2 Rest of World Based Manufacturers Vaccine Particulate Adjuvants Production Value (2021-2026)
4.6.3 Rest of World Based Manufacturers Vaccine Particulate Adjuvants Production (2021-2026)
5 MARKET ANALYSIS BY TYPE
5.1 World Vaccine Particulate Adjuvants Market Size Overview by Type: 2021 VS 2025 VS 2032
5.2 Segment Introduction by Type
5.2.1 Oral
5.2.2 Subcutaneous
5.2.3 Intranasal
5.2.4 Intramuscular
5.2.5 Intradermal
5.2.6 Others
5.3 Market Segment by Type
5.3.1 World Vaccine Particulate Adjuvants Production by Type (2021-2032)
5.3.2 World Vaccine Particulate Adjuvants Production Value by Type (2021-2032)
5.3.3 World Vaccine Particulate Adjuvants Average Price by Type (2021-2032)
6 MARKET ANALYSIS BY PARTICLE ARCHITECTURE
6.1 World Vaccine Particulate Adjuvants Market Size Overview by Particle Architecture: 2021 VS 2025 VS 2032
6.2 Segment Introduction by Particle Architecture
6.2.1 Mineral gel / precipitated particles
6.2.2 Liposomal vesicles
6.2.3 Virosomal vesicles
6.2.4 Saponin nanoparticle / ISCOM-type complexes
6.2.5 Polymeric micro- or nanoparticles
6.2.6 Others
6.3 Market Segment by Particle Architecture
6.3.1 World Vaccine Particulate Adjuvants Production by Particle Architecture (2021-2032)
6.3.2 World Vaccine Particulate Adjuvants Production Value by Particle Architecture (2021-2032)
6.3.3 World Vaccine Particulate Adjuvants Average Price by Particle Architecture (2021-2032)
7 MARKET ANALYSIS BY MATERIAL COMPOSITION
7.1 World Vaccine Particulate Adjuvants Market Size Overview by Material Composition: 2021 VS 2025 VS 2032
7.2 Segment Introduction by Material Composition
7.2.1 Aluminum salt-based particulate adjuvants
7.2.2 Phospholipid-based particulate adjuvants
7.2.3 Saponin-based particulate adjuvants
7.2.4 Polymer-based particulate adjuvants
7.2.5 Virus-membrane / virosome-based particulate adjuvants
7.2.6 Hybrid particulate systems
7.2.7 Others
7.3 Market Segment by Material Composition
7.3.1 World Vaccine Particulate Adjuvants Production by Material Composition (2021-2032)
7.3.2 World Vaccine Particulate Adjuvants Production Value by Material Composition (2021-2032)
7.3.3 World Vaccine Particulate Adjuvants Average Price by Material Composition (2021-2032)
8 MARKET ANALYSIS BY ANTIGEN ASSOCIATION MODE
8.1 World Vaccine Particulate Adjuvants Market Size Overview by Antigen Association Mode: 2021 VS 2025 VS 2032
8.2 Segment Introduction by Antigen Association Mode
8.2.1 Surface-adsorbed particulate systems
8.2.2 Encapsulated particulate systems
8.2.3 Co-assembled particulate systems
8.2.4 Admixture particulate systems
8.2.5 Others
8.3 Market Segment by Antigen Association Mode
8.3.1 World Vaccine Particulate Adjuvants Production by Antigen Association Mode (2021-2032)
8.3.2 World Vaccine Particulate Adjuvants Production Value by Antigen Association Mode (2021-2032)
8.3.3 World Vaccine Particulate Adjuvants Average Price by Antigen Association Mode (2021-2032)
9 MARKET ANALYSIS BY APPLICATION
9.1 World Vaccine Particulate Adjuvants Market Size Overview by Application: 2021 VS 2025 VS 2032
9.2 Segment Introduction by Application
9.2.1 Infectious Diseases
9.2.2 Cancer
9.2.3 Others
9.3 Market Segment by Application
9.3.1 World Vaccine Particulate Adjuvants Production by Application (2021-2032)
9.3.2 World Vaccine Particulate Adjuvants Production Value by Application (2021-2032)
9.3.3 World Vaccine Particulate Adjuvants Average Price by Application (2021-2032)
10 COMPANY PROFILES
10.1 GSK
10.1.1 GSK Details
10.1.2 GSK Major Business
10.1.3 GSK Vaccine Particulate Adjuvants Product and Services
10.1.4 GSK Vaccine Particulate Adjuvants Production, Price, Value, Gross Margin and Market Share (2021-2026)
10.1.5 GSK Recent Developments/Updates
10.1.6 GSK Competitive Strengths & Weaknesses
10.2 Merck
10.2.1 Merck Details
10.2.2 Merck Major Business
10.2.3 Merck Vaccine Particulate Adjuvants Product and Services
10.2.4 Merck Vaccine Particulate Adjuvants Production, Price, Value, Gross Margin and Market Share (2021-2026)
10.2.5 Merck Recent Developments/Updates
10.2.6 Merck Competitive Strengths & Weaknesses
10.3 Sanofi
10.3.1 Sanofi Details
10.3.2 Sanofi Major Business
10.3.3 Sanofi Vaccine Particulate Adjuvants Product and Services
10.3.4 Sanofi Vaccine Particulate Adjuvants Production, Price, Value, Gross Margin and Market Share (2021-2026)
10.3.5 Sanofi Recent Developments/Updates
10.3.6 Sanofi Competitive Strengths & Weaknesses
10.4 Croda
10.4.1 Croda Details
10.4.2 Croda Major Business
10.4.3 Croda Vaccine Particulate Adjuvants Product and Services
10.4.4 Croda Vaccine Particulate Adjuvants Production, Price, Value, Gross Margin and Market Share (2021-2026)
10.4.5 Croda Recent Developments/Updates
10.4.6 Croda Competitive Strengths & Weaknesses
10.5 Novavax
10.5.1 Novavax Details
10.5.2 Novavax Major Business
10.5.3 Novavax Vaccine Particulate Adjuvants Product and Services
10.5.4 Novavax Vaccine Particulate Adjuvants Production, Price, Value, Gross Margin and Market Share (2021-2026)
10.5.5 Novavax Recent Developments/Updates
10.5.6 Novavax Competitive Strengths & Weaknesses
10.6 SPI Pharma
10.6.1 SPI Pharma Details
10.6.2 SPI Pharma Major Business
10.6.3 SPI Pharma Vaccine Particulate Adjuvants Product and Services
10.6.4 SPI Pharma Vaccine Particulate Adjuvants Production, Price, Value, Gross Margin and Market Share (2021-2026)
10.6.5 SPI Pharma Recent Developments/Updates
10.6.6 SPI Pharma Competitive Strengths & Weaknesses
10.7 CSL
10.7.1 CSL Details
10.7.2 CSL Major Business
10.7.3 CSL Vaccine Particulate Adjuvants Product and Services
10.7.4 CSL Vaccine Particulate Adjuvants Production, Price, Value, Gross Margin and Market Share (2021-2026)
10.7.5 CSL Recent Developments/Updates
10.7.6 CSL Competitive Strengths & Weaknesses
10.8 Serum Institute of India
10.8.1 Serum Institute of India Details
10.8.2 Serum Institute of India Major Business
10.8.3 Serum Institute of India Vaccine Particulate Adjuvants Product and Services
10.8.4 Serum Institute of India Vaccine Particulate Adjuvants Production, Price, Value, Gross Margin and Market Share (2021-2026)
10.8.5 Serum Institute of India Recent Developments/Updates
10.8.6 Serum Institute of India Competitive Strengths & Weaknesses
10.9 Bharat Biotech
10.9.1 Bharat Biotech Details
10.9.2 Bharat Biotech Major Business
10.9.3 Bharat Biotech Vaccine Particulate Adjuvants Product and Services
10.9.4 Bharat Biotech Vaccine Particulate Adjuvants Production, Price, Value, Gross Margin and Market Share (2021-2026)
10.9.5 Bharat Biotech Recent Developments/Updates
10.9.6 Bharat Biotech Competitive Strengths & Weaknesses
10.10 Biological E
10.10.1 Biological E Details
10.10.2 Biological E Major Business
10.10.3 Biological E Vaccine Particulate Adjuvants Product and Services
10.10.4 Biological E Vaccine Particulate Adjuvants Production, Price, Value, Gross Margin and Market Share (2021-2026)
10.10.5 Biological E Recent Developments/Updates
10.10.6 Biological E Competitive Strengths & Weaknesses
10.11 Panacea Biotec
10.11.1 Panacea Biotec Details
10.11.2 Panacea Biotec Major Business
10.11.3 Panacea Biotec Vaccine Particulate Adjuvants Product and Services
10.11.4 Panacea Biotec Vaccine Particulate Adjuvants Production, Price, Value, Gross Margin and Market Share (2021-2026)
10.11.5 Panacea Biotec Recent Developments/Updates
10.11.6 Panacea Biotec Competitive Strengths & Weaknesses
10.12 Valneva
10.12.1 Valneva Details
10.12.2 Valneva Major Business
10.12.3 Valneva Vaccine Particulate Adjuvants Product and Services
10.12.4 Valneva Vaccine Particulate Adjuvants Production, Price, Value, Gross Margin and Market Share (2021-2026)
10.12.5 Valneva Recent Developments/Updates
10.12.6 Valneva Competitive Strengths & Weaknesses
10.13 SEPPIC
10.13.1 SEPPIC Details
10.13.2 SEPPIC Major Business
10.13.3 SEPPIC Vaccine Particulate Adjuvants Product and Services
10.13.4 SEPPIC Vaccine Particulate Adjuvants Production, Price, Value, Gross Margin and Market Share (2021-2026)
10.13.5 SEPPIC Recent Developments/Updates
10.13.6 SEPPIC Competitive Strengths & Weaknesses
10.14 Phibro Animal Health
10.14.1 Phibro Animal Health Details
10.14.2 Phibro Animal Health Major Business
10.14.3 Phibro Animal Health Vaccine Particulate Adjuvants Product and Services
10.14.4 Phibro Animal Health Vaccine Particulate Adjuvants Production, Price, Value, Gross Margin and Market Share (2021-2026)
10.14.5 Phibro Animal Health Recent Developments/Updates
10.14.6 Phibro Animal Health Competitive Strengths & Weaknesses
10.15 Aurorium
10.15.1 Aurorium Details
10.15.2 Aurorium Major Business
10.15.3 Aurorium Vaccine Particulate Adjuvants Product and Services
10.15.4 Aurorium Vaccine Particulate Adjuvants Production, Price, Value, Gross Margin and Market Share (2021-2026)
10.15.5 Aurorium Recent Developments/Updates
10.15.6 Aurorium Competitive Strengths & Weaknesses
10.16 Agenus
10.16.1 Agenus Details
10.16.2 Agenus Major Business
10.16.3 Agenus Vaccine Particulate Adjuvants Product and Services
10.16.4 Agenus Vaccine Particulate Adjuvants Production, Price, Value, Gross Margin and Market Share (2021-2026)
10.16.5 Agenus Recent Developments/Updates
10.16.6 Agenus Competitive Strengths & Weaknesses
10.17 InvivoGen
10.17.1 InvivoGen Details
10.17.2 InvivoGen Major Business
10.17.3 InvivoGen Vaccine Particulate Adjuvants Product and Services
10.17.4 InvivoGen Vaccine Particulate Adjuvants Production, Price, Value, Gross Margin and Market Share (2021-2026)
10.17.5 InvivoGen Recent Developments/Updates
10.17.6 InvivoGen Competitive Strengths & Weaknesses
10.18 OZ Biosciences
10.18.1 OZ Biosciences Details
10.18.2 OZ Biosciences Major Business
10.18.3 OZ Biosciences Vaccine Particulate Adjuvants Product and Services
10.18.4 OZ Biosciences Vaccine Particulate Adjuvants Production, Price, Value, Gross Margin and Market Share (2021-2026)
10.18.5 OZ Biosciences Recent Developments/Updates
10.18.6 OZ Biosciences Competitive Strengths & Weaknesses
10.19 Vaxine
10.19.1 Vaxine Details
10.19.2 Vaxine Major Business
10.19.3 Vaxine Vaccine Particulate Adjuvants Product and Services
10.19.4 Vaxine Vaccine Particulate Adjuvants Production, Price, Value, Gross Margin and Market Share (2021-2026)
10.19.5 Vaxine Recent Developments/Updates
10.19.6 Vaxine Competitive Strengths & Weaknesses
10.20 Adjuvatis
10.20.1 Adjuvatis Details
10.20.2 Adjuvatis Major Business
10.20.3 Adjuvatis Vaccine Particulate Adjuvants Product and Services
10.20.4 Adjuvatis Vaccine Particulate Adjuvants Production, Price, Value, Gross Margin and Market Share (2021-2026)
10.20.5 Adjuvatis Recent Developments/Updates
10.20.6 Adjuvatis Competitive Strengths & Weaknesses
10.21 Desert King
10.21.1 Desert King Details
10.21.2 Desert King Major Business
10.21.3 Desert King Vaccine Particulate Adjuvants Product and Services
10.21.4 Desert King Vaccine Particulate Adjuvants Production, Price, Value, Gross Margin and Market Share (2021-2026)
10.21.5 Desert King Recent Developments/Updates
10.21.6 Desert King Competitive Strengths & Weaknesses
10.22 Sinovac
10.22.1 Sinovac Details
10.22.2 Sinovac Major Business
10.22.3 Sinovac Vaccine Particulate Adjuvants Product and Services
10.22.4 Sinovac Vaccine Particulate Adjuvants Production, Price, Value, Gross Margin and Market Share (2021-2026)
10.22.5 Sinovac Recent Developments/Updates
10.22.6 Sinovac Competitive Strengths & Weaknesses
10.23 China National Biotec Group
10.23.1 China National Biotec Group Details
10.23.2 China National Biotec Group Major Business
10.23.3 China National Biotec Group Vaccine Particulate Adjuvants Product and Services
10.23.4 China National Biotec Group Vaccine Particulate Adjuvants Production, Price, Value, Gross Margin and Market Share (2021-2026)
10.23.5 China National Biotec Group Recent Developments/Updates
10.23.6 China National Biotec Group Competitive Strengths & Weaknesses
10.24 Walvax
10.24.1 Walvax Details
10.24.2 Walvax Major Business
10.24.3 Walvax Vaccine Particulate Adjuvants Product and Services
10.24.4 Walvax Vaccine Particulate Adjuvants Production, Price, Value, Gross Margin and Market Share (2021-2026)
10.24.5 Walvax Recent Developments/Updates
10.24.6 Walvax Competitive Strengths & Weaknesses
10.25 Anhui Zhifei Longcom
10.25.1 Anhui Zhifei Longcom Details
10.25.2 Anhui Zhifei Longcom Major Business
10.25.3 Anhui Zhifei Longcom Vaccine Particulate Adjuvants Product and Services
10.25.4 Anhui Zhifei Longcom Vaccine Particulate Adjuvants Production, Price, Value, Gross Margin and Market Share (2021-2026)
10.25.5 Anhui Zhifei Longcom Recent Developments/Updates
10.25.6 Anhui Zhifei Longcom Competitive Strengths & Weaknesses
11 INDUSTRY CHAIN ANALYSIS
11.1 Vaccine Particulate Adjuvants Industry Chain
11.2 Vaccine Particulate Adjuvants Upstream Analysis
11.2.1 Vaccine Particulate Adjuvants Core Raw Materials
11.2.2 Main Manufacturers of Vaccine Particulate Adjuvants Core Raw Materials
11.3 Midstream Analysis
11.4 Downstream Analysis
11.5 Vaccine Particulate Adjuvants Production Mode
11.6 Vaccine Particulate Adjuvants Procurement Model
11.7 Vaccine Particulate Adjuvants Industry Sales Model and Sales Channels
11.7.1 Vaccine Particulate Adjuvants Sales Model
11.7.2 Vaccine Particulate Adjuvants Typical Distributors
12 RESEARCH FINDINGS AND CONCLUSION
13 APPENDIX
13.1 Methodology
13.2 Research Process and Data Source
13.3 Disclaimer
1.1 Vaccine Particulate Adjuvants Introduction
1.2 World Vaccine Particulate Adjuvants Supply & Forecast
1.2.1 World Vaccine Particulate Adjuvants Production Value (2021 & 2025 & 2032)
1.2.2 World Vaccine Particulate Adjuvants Production (2021-2032)
1.2.3 World Vaccine Particulate Adjuvants Pricing Trends (2021-2032)
1.3 World Vaccine Particulate Adjuvants Production by Region (Based on Production Site)
1.3.1 World Vaccine Particulate Adjuvants Production Value by Region (2021-2032)
1.3.2 World Vaccine Particulate Adjuvants Production by Region (2021-2032)
1.3.3 World Vaccine Particulate Adjuvants Average Price by Region (2021-2032)
1.3.4 Europe Vaccine Particulate Adjuvants Production (2021-2032)
1.3.5 North America Vaccine Particulate Adjuvants Production (2021-2032)
1.3.6 China Vaccine Particulate Adjuvants Production (2021-2032)
1.3.7 South Korea Vaccine Particulate Adjuvants Production (2021-2032)
1.3.8 India Vaccine Particulate Adjuvants Production (2021-2032)
1.3.9 Australia Vaccine Particulate Adjuvants Production (2021-2032)
1.4 Market Drivers, Restraints and Trends
1.4.1 Vaccine Particulate Adjuvants Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Vaccine Particulate Adjuvants Major Market Trends
2 DEMAND SUMMARY
2.1 World Vaccine Particulate Adjuvants Demand (2021-2032)
2.2 World Vaccine Particulate Adjuvants Consumption by Region
2.2.1 World Vaccine Particulate Adjuvants Consumption by Region (2021-2026)
2.2.2 World Vaccine Particulate Adjuvants Consumption Forecast by Region (2027-2032)
2.3 United States Vaccine Particulate Adjuvants Consumption (2021-2032)
2.4 China Vaccine Particulate Adjuvants Consumption (2021-2032)
2.5 Europe Vaccine Particulate Adjuvants Consumption (2021-2032)
2.6 Japan Vaccine Particulate Adjuvants Consumption (2021-2032)
2.7 South Korea Vaccine Particulate Adjuvants Consumption (2021-2032)
2.8 ASEAN Vaccine Particulate Adjuvants Consumption (2021-2032)
2.9 India Vaccine Particulate Adjuvants Consumption (2021-2032)
3 WORLD MANUFACTURERS COMPETITIVE ANALYSIS
3.1 World Vaccine Particulate Adjuvants Production Value by Manufacturer (2021-2026)
3.2 World Vaccine Particulate Adjuvants Production by Manufacturer (2021-2026)
3.3 World Vaccine Particulate Adjuvants Average Price by Manufacturer (2021-2026)
3.4 Vaccine Particulate Adjuvants Company Evaluation Quadrant
3.5 Industry Rank and Concentration Rate (CR)
3.5.1 Global Vaccine Particulate Adjuvants Industry Rank of Major Manufacturers
3.5.2 Global Concentration Ratios (CR4) for Vaccine Particulate Adjuvants in 2025
3.5.3 Global Concentration Ratios (CR8) for Vaccine Particulate Adjuvants in 2025
3.6 Vaccine Particulate Adjuvants Market: Overall Company Footprint Analysis
3.6.1 Vaccine Particulate Adjuvants Market: Region Footprint
3.6.2 Vaccine Particulate Adjuvants Market: Company Product Type Footprint
3.6.3 Vaccine Particulate Adjuvants Market: Company Product Application Footprint
3.7 Competitive Environment
3.7.1 Historical Structure of the Industry
3.7.2 Barriers of Market Entry
3.7.3 Factors of Competition
3.8 New Entrant and Capacity Expansion Plans
3.9 Mergers, Acquisition, Agreements, and Collaborations
4 UNITED STATES VS CHINA VS REST OF THE WORLD
4.1 United States VS China: Vaccine Particulate Adjuvants Production Value Comparison
4.1.1 United States VS China: Vaccine Particulate Adjuvants Production Value Comparison (2021 & 2025 & 2032)
4.1.2 United States VS China: Vaccine Particulate Adjuvants Production Value Market Share Comparison (2021 & 2025 & 2032)
4.2 United States VS China: Vaccine Particulate Adjuvants Production Comparison
4.2.1 United States VS China: Vaccine Particulate Adjuvants Production Comparison (2021 & 2025 & 2032)
4.2.2 United States VS China: Vaccine Particulate Adjuvants Production Market Share Comparison (2021 & 2025 & 2032)
4.3 United States VS China: Vaccine Particulate Adjuvants Consumption Comparison
4.3.1 United States VS China: Vaccine Particulate Adjuvants Consumption Comparison (2021 & 2025 & 2032)
4.3.2 United States VS China: Vaccine Particulate Adjuvants Consumption Market Share Comparison (2021 & 2025 & 2032)
4.4 United States Based Vaccine Particulate Adjuvants Manufacturers and Market Share, 2021-2026
4.4.1 United States Based Vaccine Particulate Adjuvants Manufacturers, Headquarters and Production Site (States, Country)
4.4.2 United States Based Manufacturers Vaccine Particulate Adjuvants Production Value (2021-2026)
4.4.3 United States Based Manufacturers Vaccine Particulate Adjuvants Production (2021-2026)
4.5 China Based Vaccine Particulate Adjuvants Manufacturers and Market Share
4.5.1 China Based Vaccine Particulate Adjuvants Manufacturers, Headquarters and Production Site (Province, Country)
4.5.2 China Based Manufacturers Vaccine Particulate Adjuvants Production Value (2021-2026)
4.5.3 China Based Manufacturers Vaccine Particulate Adjuvants Production (2021-2026)
4.6 Rest of World Based Vaccine Particulate Adjuvants Manufacturers and Market Share, 2021-2026
4.6.1 Rest of World Based Vaccine Particulate Adjuvants Manufacturers, Headquarters and Production Site (State, Country)
4.6.2 Rest of World Based Manufacturers Vaccine Particulate Adjuvants Production Value (2021-2026)
4.6.3 Rest of World Based Manufacturers Vaccine Particulate Adjuvants Production (2021-2026)
5 MARKET ANALYSIS BY TYPE
5.1 World Vaccine Particulate Adjuvants Market Size Overview by Type: 2021 VS 2025 VS 2032
5.2 Segment Introduction by Type
5.2.1 Oral
5.2.2 Subcutaneous
5.2.3 Intranasal
5.2.4 Intramuscular
5.2.5 Intradermal
5.2.6 Others
5.3 Market Segment by Type
5.3.1 World Vaccine Particulate Adjuvants Production by Type (2021-2032)
5.3.2 World Vaccine Particulate Adjuvants Production Value by Type (2021-2032)
5.3.3 World Vaccine Particulate Adjuvants Average Price by Type (2021-2032)
6 MARKET ANALYSIS BY PARTICLE ARCHITECTURE
6.1 World Vaccine Particulate Adjuvants Market Size Overview by Particle Architecture: 2021 VS 2025 VS 2032
6.2 Segment Introduction by Particle Architecture
6.2.1 Mineral gel / precipitated particles
6.2.2 Liposomal vesicles
6.2.3 Virosomal vesicles
6.2.4 Saponin nanoparticle / ISCOM-type complexes
6.2.5 Polymeric micro- or nanoparticles
6.2.6 Others
6.3 Market Segment by Particle Architecture
6.3.1 World Vaccine Particulate Adjuvants Production by Particle Architecture (2021-2032)
6.3.2 World Vaccine Particulate Adjuvants Production Value by Particle Architecture (2021-2032)
6.3.3 World Vaccine Particulate Adjuvants Average Price by Particle Architecture (2021-2032)
7 MARKET ANALYSIS BY MATERIAL COMPOSITION
7.1 World Vaccine Particulate Adjuvants Market Size Overview by Material Composition: 2021 VS 2025 VS 2032
7.2 Segment Introduction by Material Composition
7.2.1 Aluminum salt-based particulate adjuvants
7.2.2 Phospholipid-based particulate adjuvants
7.2.3 Saponin-based particulate adjuvants
7.2.4 Polymer-based particulate adjuvants
7.2.5 Virus-membrane / virosome-based particulate adjuvants
7.2.6 Hybrid particulate systems
7.2.7 Others
7.3 Market Segment by Material Composition
7.3.1 World Vaccine Particulate Adjuvants Production by Material Composition (2021-2032)
7.3.2 World Vaccine Particulate Adjuvants Production Value by Material Composition (2021-2032)
7.3.3 World Vaccine Particulate Adjuvants Average Price by Material Composition (2021-2032)
8 MARKET ANALYSIS BY ANTIGEN ASSOCIATION MODE
8.1 World Vaccine Particulate Adjuvants Market Size Overview by Antigen Association Mode: 2021 VS 2025 VS 2032
8.2 Segment Introduction by Antigen Association Mode
8.2.1 Surface-adsorbed particulate systems
8.2.2 Encapsulated particulate systems
8.2.3 Co-assembled particulate systems
8.2.4 Admixture particulate systems
8.2.5 Others
8.3 Market Segment by Antigen Association Mode
8.3.1 World Vaccine Particulate Adjuvants Production by Antigen Association Mode (2021-2032)
8.3.2 World Vaccine Particulate Adjuvants Production Value by Antigen Association Mode (2021-2032)
8.3.3 World Vaccine Particulate Adjuvants Average Price by Antigen Association Mode (2021-2032)
9 MARKET ANALYSIS BY APPLICATION
9.1 World Vaccine Particulate Adjuvants Market Size Overview by Application: 2021 VS 2025 VS 2032
9.2 Segment Introduction by Application
9.2.1 Infectious Diseases
9.2.2 Cancer
9.2.3 Others
9.3 Market Segment by Application
9.3.1 World Vaccine Particulate Adjuvants Production by Application (2021-2032)
9.3.2 World Vaccine Particulate Adjuvants Production Value by Application (2021-2032)
9.3.3 World Vaccine Particulate Adjuvants Average Price by Application (2021-2032)
10 COMPANY PROFILES
10.1 GSK
10.1.1 GSK Details
10.1.2 GSK Major Business
10.1.3 GSK Vaccine Particulate Adjuvants Product and Services
10.1.4 GSK Vaccine Particulate Adjuvants Production, Price, Value, Gross Margin and Market Share (2021-2026)
10.1.5 GSK Recent Developments/Updates
10.1.6 GSK Competitive Strengths & Weaknesses
10.2 Merck
10.2.1 Merck Details
10.2.2 Merck Major Business
10.2.3 Merck Vaccine Particulate Adjuvants Product and Services
10.2.4 Merck Vaccine Particulate Adjuvants Production, Price, Value, Gross Margin and Market Share (2021-2026)
10.2.5 Merck Recent Developments/Updates
10.2.6 Merck Competitive Strengths & Weaknesses
10.3 Sanofi
10.3.1 Sanofi Details
10.3.2 Sanofi Major Business
10.3.3 Sanofi Vaccine Particulate Adjuvants Product and Services
10.3.4 Sanofi Vaccine Particulate Adjuvants Production, Price, Value, Gross Margin and Market Share (2021-2026)
10.3.5 Sanofi Recent Developments/Updates
10.3.6 Sanofi Competitive Strengths & Weaknesses
10.4 Croda
10.4.1 Croda Details
10.4.2 Croda Major Business
10.4.3 Croda Vaccine Particulate Adjuvants Product and Services
10.4.4 Croda Vaccine Particulate Adjuvants Production, Price, Value, Gross Margin and Market Share (2021-2026)
10.4.5 Croda Recent Developments/Updates
10.4.6 Croda Competitive Strengths & Weaknesses
10.5 Novavax
10.5.1 Novavax Details
10.5.2 Novavax Major Business
10.5.3 Novavax Vaccine Particulate Adjuvants Product and Services
10.5.4 Novavax Vaccine Particulate Adjuvants Production, Price, Value, Gross Margin and Market Share (2021-2026)
10.5.5 Novavax Recent Developments/Updates
10.5.6 Novavax Competitive Strengths & Weaknesses
10.6 SPI Pharma
10.6.1 SPI Pharma Details
10.6.2 SPI Pharma Major Business
10.6.3 SPI Pharma Vaccine Particulate Adjuvants Product and Services
10.6.4 SPI Pharma Vaccine Particulate Adjuvants Production, Price, Value, Gross Margin and Market Share (2021-2026)
10.6.5 SPI Pharma Recent Developments/Updates
10.6.6 SPI Pharma Competitive Strengths & Weaknesses
10.7 CSL
10.7.1 CSL Details
10.7.2 CSL Major Business
10.7.3 CSL Vaccine Particulate Adjuvants Product and Services
10.7.4 CSL Vaccine Particulate Adjuvants Production, Price, Value, Gross Margin and Market Share (2021-2026)
10.7.5 CSL Recent Developments/Updates
10.7.6 CSL Competitive Strengths & Weaknesses
10.8 Serum Institute of India
10.8.1 Serum Institute of India Details
10.8.2 Serum Institute of India Major Business
10.8.3 Serum Institute of India Vaccine Particulate Adjuvants Product and Services
10.8.4 Serum Institute of India Vaccine Particulate Adjuvants Production, Price, Value, Gross Margin and Market Share (2021-2026)
10.8.5 Serum Institute of India Recent Developments/Updates
10.8.6 Serum Institute of India Competitive Strengths & Weaknesses
10.9 Bharat Biotech
10.9.1 Bharat Biotech Details
10.9.2 Bharat Biotech Major Business
10.9.3 Bharat Biotech Vaccine Particulate Adjuvants Product and Services
10.9.4 Bharat Biotech Vaccine Particulate Adjuvants Production, Price, Value, Gross Margin and Market Share (2021-2026)
10.9.5 Bharat Biotech Recent Developments/Updates
10.9.6 Bharat Biotech Competitive Strengths & Weaknesses
10.10 Biological E
10.10.1 Biological E Details
10.10.2 Biological E Major Business
10.10.3 Biological E Vaccine Particulate Adjuvants Product and Services
10.10.4 Biological E Vaccine Particulate Adjuvants Production, Price, Value, Gross Margin and Market Share (2021-2026)
10.10.5 Biological E Recent Developments/Updates
10.10.6 Biological E Competitive Strengths & Weaknesses
10.11 Panacea Biotec
10.11.1 Panacea Biotec Details
10.11.2 Panacea Biotec Major Business
10.11.3 Panacea Biotec Vaccine Particulate Adjuvants Product and Services
10.11.4 Panacea Biotec Vaccine Particulate Adjuvants Production, Price, Value, Gross Margin and Market Share (2021-2026)
10.11.5 Panacea Biotec Recent Developments/Updates
10.11.6 Panacea Biotec Competitive Strengths & Weaknesses
10.12 Valneva
10.12.1 Valneva Details
10.12.2 Valneva Major Business
10.12.3 Valneva Vaccine Particulate Adjuvants Product and Services
10.12.4 Valneva Vaccine Particulate Adjuvants Production, Price, Value, Gross Margin and Market Share (2021-2026)
10.12.5 Valneva Recent Developments/Updates
10.12.6 Valneva Competitive Strengths & Weaknesses
10.13 SEPPIC
10.13.1 SEPPIC Details
10.13.2 SEPPIC Major Business
10.13.3 SEPPIC Vaccine Particulate Adjuvants Product and Services
10.13.4 SEPPIC Vaccine Particulate Adjuvants Production, Price, Value, Gross Margin and Market Share (2021-2026)
10.13.5 SEPPIC Recent Developments/Updates
10.13.6 SEPPIC Competitive Strengths & Weaknesses
10.14 Phibro Animal Health
10.14.1 Phibro Animal Health Details
10.14.2 Phibro Animal Health Major Business
10.14.3 Phibro Animal Health Vaccine Particulate Adjuvants Product and Services
10.14.4 Phibro Animal Health Vaccine Particulate Adjuvants Production, Price, Value, Gross Margin and Market Share (2021-2026)
10.14.5 Phibro Animal Health Recent Developments/Updates
10.14.6 Phibro Animal Health Competitive Strengths & Weaknesses
10.15 Aurorium
10.15.1 Aurorium Details
10.15.2 Aurorium Major Business
10.15.3 Aurorium Vaccine Particulate Adjuvants Product and Services
10.15.4 Aurorium Vaccine Particulate Adjuvants Production, Price, Value, Gross Margin and Market Share (2021-2026)
10.15.5 Aurorium Recent Developments/Updates
10.15.6 Aurorium Competitive Strengths & Weaknesses
10.16 Agenus
10.16.1 Agenus Details
10.16.2 Agenus Major Business
10.16.3 Agenus Vaccine Particulate Adjuvants Product and Services
10.16.4 Agenus Vaccine Particulate Adjuvants Production, Price, Value, Gross Margin and Market Share (2021-2026)
10.16.5 Agenus Recent Developments/Updates
10.16.6 Agenus Competitive Strengths & Weaknesses
10.17 InvivoGen
10.17.1 InvivoGen Details
10.17.2 InvivoGen Major Business
10.17.3 InvivoGen Vaccine Particulate Adjuvants Product and Services
10.17.4 InvivoGen Vaccine Particulate Adjuvants Production, Price, Value, Gross Margin and Market Share (2021-2026)
10.17.5 InvivoGen Recent Developments/Updates
10.17.6 InvivoGen Competitive Strengths & Weaknesses
10.18 OZ Biosciences
10.18.1 OZ Biosciences Details
10.18.2 OZ Biosciences Major Business
10.18.3 OZ Biosciences Vaccine Particulate Adjuvants Product and Services
10.18.4 OZ Biosciences Vaccine Particulate Adjuvants Production, Price, Value, Gross Margin and Market Share (2021-2026)
10.18.5 OZ Biosciences Recent Developments/Updates
10.18.6 OZ Biosciences Competitive Strengths & Weaknesses
10.19 Vaxine
10.19.1 Vaxine Details
10.19.2 Vaxine Major Business
10.19.3 Vaxine Vaccine Particulate Adjuvants Product and Services
10.19.4 Vaxine Vaccine Particulate Adjuvants Production, Price, Value, Gross Margin and Market Share (2021-2026)
10.19.5 Vaxine Recent Developments/Updates
10.19.6 Vaxine Competitive Strengths & Weaknesses
10.20 Adjuvatis
10.20.1 Adjuvatis Details
10.20.2 Adjuvatis Major Business
10.20.3 Adjuvatis Vaccine Particulate Adjuvants Product and Services
10.20.4 Adjuvatis Vaccine Particulate Adjuvants Production, Price, Value, Gross Margin and Market Share (2021-2026)
10.20.5 Adjuvatis Recent Developments/Updates
10.20.6 Adjuvatis Competitive Strengths & Weaknesses
10.21 Desert King
10.21.1 Desert King Details
10.21.2 Desert King Major Business
10.21.3 Desert King Vaccine Particulate Adjuvants Product and Services
10.21.4 Desert King Vaccine Particulate Adjuvants Production, Price, Value, Gross Margin and Market Share (2021-2026)
10.21.5 Desert King Recent Developments/Updates
10.21.6 Desert King Competitive Strengths & Weaknesses
10.22 Sinovac
10.22.1 Sinovac Details
10.22.2 Sinovac Major Business
10.22.3 Sinovac Vaccine Particulate Adjuvants Product and Services
10.22.4 Sinovac Vaccine Particulate Adjuvants Production, Price, Value, Gross Margin and Market Share (2021-2026)
10.22.5 Sinovac Recent Developments/Updates
10.22.6 Sinovac Competitive Strengths & Weaknesses
10.23 China National Biotec Group
10.23.1 China National Biotec Group Details
10.23.2 China National Biotec Group Major Business
10.23.3 China National Biotec Group Vaccine Particulate Adjuvants Product and Services
10.23.4 China National Biotec Group Vaccine Particulate Adjuvants Production, Price, Value, Gross Margin and Market Share (2021-2026)
10.23.5 China National Biotec Group Recent Developments/Updates
10.23.6 China National Biotec Group Competitive Strengths & Weaknesses
10.24 Walvax
10.24.1 Walvax Details
10.24.2 Walvax Major Business
10.24.3 Walvax Vaccine Particulate Adjuvants Product and Services
10.24.4 Walvax Vaccine Particulate Adjuvants Production, Price, Value, Gross Margin and Market Share (2021-2026)
10.24.5 Walvax Recent Developments/Updates
10.24.6 Walvax Competitive Strengths & Weaknesses
10.25 Anhui Zhifei Longcom
10.25.1 Anhui Zhifei Longcom Details
10.25.2 Anhui Zhifei Longcom Major Business
10.25.3 Anhui Zhifei Longcom Vaccine Particulate Adjuvants Product and Services
10.25.4 Anhui Zhifei Longcom Vaccine Particulate Adjuvants Production, Price, Value, Gross Margin and Market Share (2021-2026)
10.25.5 Anhui Zhifei Longcom Recent Developments/Updates
10.25.6 Anhui Zhifei Longcom Competitive Strengths & Weaknesses
11 INDUSTRY CHAIN ANALYSIS
11.1 Vaccine Particulate Adjuvants Industry Chain
11.2 Vaccine Particulate Adjuvants Upstream Analysis
11.2.1 Vaccine Particulate Adjuvants Core Raw Materials
11.2.2 Main Manufacturers of Vaccine Particulate Adjuvants Core Raw Materials
11.3 Midstream Analysis
11.4 Downstream Analysis
11.5 Vaccine Particulate Adjuvants Production Mode
11.6 Vaccine Particulate Adjuvants Procurement Model
11.7 Vaccine Particulate Adjuvants Industry Sales Model and Sales Channels
11.7.1 Vaccine Particulate Adjuvants Sales Model
11.7.2 Vaccine Particulate Adjuvants Typical Distributors
12 RESEARCH FINDINGS AND CONCLUSION
13 APPENDIX
13.1 Methodology
13.2 Research Process and Data Source
13.3 Disclaimer
LIST OF TABLES
Table 1. World Vaccine Particulate Adjuvants Production Value by Region (2021, 2025 and 2032) & (USD Million)
Table 2. World Vaccine Particulate Adjuvants Production Value by Region (2021-2026) & (USD Million)
Table 3. World Vaccine Particulate Adjuvants Production Value by Region (2027-2032) & (USD Million)
Table 4. World Vaccine Particulate Adjuvants Production Value Market Share by Region (2021-2026)
Table 5. World Vaccine Particulate Adjuvants Production Value Market Share by Region (2027-2032)
Table 6. World Vaccine Particulate Adjuvants Production by Region (2021-2026) & (K Units)
Table 7. World Vaccine Particulate Adjuvants Production by Region (2027-2032) & (K Units)
Table 8. World Vaccine Particulate Adjuvants Production Market Share by Region (2021-2026)
Table 9. World Vaccine Particulate Adjuvants Production Market Share by Region (2027-2032)
Table 10. World Vaccine Particulate Adjuvants Average Price by Region (2021-2026) & (US$/Unit)
Table 11. World Vaccine Particulate Adjuvants Average Price by Region (2027-2032) & (US$/Unit)
Table 12. Vaccine Particulate Adjuvants Major Market Trends
Table 13. World Vaccine Particulate Adjuvants Consumption Growth Rate Forecast by Region (2021 & 2025 & 2032) & (K Units)
Table 14. World Vaccine Particulate Adjuvants Consumption by Region (2021-2026) & (K Units)
Table 15. World Vaccine Particulate Adjuvants Consumption Forecast by Region (2027-2032) & (K Units)
Table 16. World Vaccine Particulate Adjuvants Production Value by Manufacturer (2021-2026) & (USD Million)
Table 17. Production Value Market Share of Key Vaccine Particulate Adjuvants Producers in 2025
Table 18. World Vaccine Particulate Adjuvants Production by Manufacturer (2021-2026) & (K Units)
Table 19. Production Market Share of Key Vaccine Particulate Adjuvants Producers in 2025
Table 20. World Vaccine Particulate Adjuvants Average Price by Manufacturer (2021-2026) & (US$/Unit)
Table 21. Global Vaccine Particulate Adjuvants Company Evaluation Quadrant
Table 22. World Vaccine Particulate Adjuvants Industry Rank of Major Manufacturers, Based on Production Value in 2025
Table 23. Head Office and Vaccine Particulate Adjuvants Production Site of Key Manufacturer
Table 24. Vaccine Particulate Adjuvants Market: Company Product Type Footprint
Table 25. Vaccine Particulate Adjuvants Market: Company Product Application Footprint
Table 26. Vaccine Particulate Adjuvants Competitive Factors
Table 27. Vaccine Particulate Adjuvants New Entrant and Capacity Expansion Plans
Table 28. Vaccine Particulate Adjuvants Mergers & Acquisitions Activity
Table 29. United States VS China Vaccine Particulate Adjuvants Production Value Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 30. United States VS China Vaccine Particulate Adjuvants Production Comparison, (2021 & 2025 & 2032) & (K Units)
Table 31. United States VS China Vaccine Particulate Adjuvants Consumption Comparison, (2021 & 2025 & 2032) & (K Units)
Table 32. United States Based Vaccine Particulate Adjuvants Manufacturers, Headquarters and Production Site (States, Country)
Table 33. United States Based Manufacturers Vaccine Particulate Adjuvants Production Value, (2021-2026) & (USD Million)
Table 34. United States Based Manufacturers Vaccine Particulate Adjuvants Production Value Market Share (2021-2026)
Table 35. United States Based Manufacturers Vaccine Particulate Adjuvants Production (2021-2026) & (K Units)
Table 36. United States Based Manufacturers Vaccine Particulate Adjuvants Production Market Share (2021-2026)
Table 37. China Based Vaccine Particulate Adjuvants Manufacturers, Headquarters and Production Site (Province, Country)
Table 38. China Based Manufacturers Vaccine Particulate Adjuvants Production Value, (2021-2026) & (USD Million)
Table 39. China Based Manufacturers Vaccine Particulate Adjuvants Production Value Market Share (2021-2026)
Table 40. China Based Manufacturers Vaccine Particulate Adjuvants Production, (2021-2026) & (K Units)
Table 41. China Based Manufacturers Vaccine Particulate Adjuvants Production Market Share (2021-2026)
Table 42. Rest of World Based Vaccine Particulate Adjuvants Manufacturers, Headquarters and Production Site (State, Country)
Table 43. Rest of World Based Manufacturers Vaccine Particulate Adjuvants Production Value, (2021-2026) & (USD Million)
Table 44. Rest of World Based Manufacturers Vaccine Particulate Adjuvants Production Value Market Share (2021-2026)
Table 45. Rest of World Based Manufacturers Vaccine Particulate Adjuvants Production, (2021-2026) & (K Units)
Table 46. Rest of World Based Manufacturers Vaccine Particulate Adjuvants Production Market Share (2021-2026)
Table 47. World Vaccine Particulate Adjuvants Production Value by Type, (USD Million), 2021 & 2025 & 2032
Table 48. World Vaccine Particulate Adjuvants Production by Type (2021-2026) & (K Units)
Table 49. World Vaccine Particulate Adjuvants Production by Type (2027-2032) & (K Units)
Table 50. World Vaccine Particulate Adjuvants Production Value by Type (2021-2026) & (USD Million)
Table 51. World Vaccine Particulate Adjuvants Production Value by Type (2027-2032) & (USD Million)
Table 52. World Vaccine Particulate Adjuvants Average Price by Type (2021-2026) & (US$/Unit)
Table 53. World Vaccine Particulate Adjuvants Average Price by Type (2027-2032) & (US$/Unit)
Table 54. World Vaccine Particulate Adjuvants Production Value by Particle Architecture, (USD Million), 2021 & 2025 & 2032
Table 55. World Vaccine Particulate Adjuvants Production by Particle Architecture (2021-2026) & (K Units)
Table 56. World Vaccine Particulate Adjuvants Production by Particle Architecture (2027-2032) & (K Units)
Table 57. World Vaccine Particulate Adjuvants Production Value by Particle Architecture (2021-2026) & (USD Million)
Table 58. World Vaccine Particulate Adjuvants Production Value by Particle Architecture (2027-2032) & (USD Million)
Table 59. World Vaccine Particulate Adjuvants Average Price by Particle Architecture (2021-2026) & (US$/Unit)
Table 60. World Vaccine Particulate Adjuvants Average Price by Particle Architecture (2027-2032) & (US$/Unit)
Table 61. World Vaccine Particulate Adjuvants Production Value by Material Composition, (USD Million), 2021 & 2025 & 2032
Table 62. World Vaccine Particulate Adjuvants Production by Material Composition (2021-2026) & (K Units)
Table 63. World Vaccine Particulate Adjuvants Production by Material Composition (2027-2032) & (K Units)
Table 64. World Vaccine Particulate Adjuvants Production Value by Material Composition (2021-2026) & (USD Million)
Table 65. World Vaccine Particulate Adjuvants Production Value by Material Composition (2027-2032) & (USD Million)
Table 66. World Vaccine Particulate Adjuvants Average Price by Material Composition (2021-2026) & (US$/Unit)
Table 67. World Vaccine Particulate Adjuvants Average Price by Material Composition (2027-2032) & (US$/Unit)
Table 68. World Vaccine Particulate Adjuvants Production Value by Antigen Association Mode, (USD Million), 2021 & 2025 & 2032
Table 69. World Vaccine Particulate Adjuvants Production by Antigen Association Mode (2021-2026) & (K Units)
Table 70. World Vaccine Particulate Adjuvants Production by Antigen Association Mode (2027-2032) & (K Units)
Table 71. World Vaccine Particulate Adjuvants Production Value by Antigen Association Mode (2021-2026) & (USD Million)
Table 72. World Vaccine Particulate Adjuvants Production Value by Antigen Association Mode (2027-2032) & (USD Million)
Table 73. World Vaccine Particulate Adjuvants Average Price by Antigen Association Mode (2021-2026) & (US$/Unit)
Table 74. World Vaccine Particulate Adjuvants Average Price by Antigen Association Mode (2027-2032) & (US$/Unit)
Table 75. World Vaccine Particulate Adjuvants Production Value by Application, (USD Million), 2021 & 2025 & 2032
Table 76. World Vaccine Particulate Adjuvants Production by Application (2021-2026) & (K Units)
Table 77. World Vaccine Particulate Adjuvants Production by Application (2027-2032) & (K Units)
Table 78. World Vaccine Particulate Adjuvants Production Value by Application (2021-2026) & (USD Million)
Table 79. World Vaccine Particulate Adjuvants Production Value by Application (2027-2032) & (USD Million)
Table 80. World Vaccine Particulate Adjuvants Average Price by Application (2021-2026) & (US$/Unit)
Table 81. World Vaccine Particulate Adjuvants Average Price by Application (2027-2032) & (US$/Unit)
Table 82. GSK Basic Information, Manufacturing Base and Competitors
Table 83. GSK Major Business
Table 84. GSK Vaccine Particulate Adjuvants Product and Services
Table 85. GSK Vaccine Particulate Adjuvants Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 86. GSK Recent Developments/Updates
Table 87. GSK Competitive Strengths & Weaknesses
Table 88. Merck Basic Information, Manufacturing Base and Competitors
Table 89. Merck Major Business
Table 90. Merck Vaccine Particulate Adjuvants Product and Services
Table 91. Merck Vaccine Particulate Adjuvants Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 92. Merck Recent Developments/Updates
Table 93. Merck Competitive Strengths & Weaknesses
Table 94. Sanofi Basic Information, Manufacturing Base and Competitors
Table 95. Sanofi Major Business
Table 96. Sanofi Vaccine Particulate Adjuvants Product and Services
Table 97. Sanofi Vaccine Particulate Adjuvants Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 98. Sanofi Recent Developments/Updates
Table 99. Sanofi Competitive Strengths & Weaknesses
Table 100. Croda Basic Information, Manufacturing Base and Competitors
Table 101. Croda Major Business
Table 102. Croda Vaccine Particulate Adjuvants Product and Services
Table 103. Croda Vaccine Particulate Adjuvants Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 104. Croda Recent Developments/Updates
Table 105. Croda Competitive Strengths & Weaknesses
Table 106. Novavax Basic Information, Manufacturing Base and Competitors
Table 107. Novavax Major Business
Table 108. Novavax Vaccine Particulate Adjuvants Product and Services
Table 109. Novavax Vaccine Particulate Adjuvants Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 110. Novavax Recent Developments/Updates
Table 111. Novavax Competitive Strengths & Weaknesses
Table 112. SPI Pharma Basic Information, Manufacturing Base and Competitors
Table 113. SPI Pharma Major Business
Table 114. SPI Pharma Vaccine Particulate Adjuvants Product and Services
Table 115. SPI Pharma Vaccine Particulate Adjuvants Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 116. SPI Pharma Recent Developments/Updates
Table 117. SPI Pharma Competitive Strengths & Weaknesses
Table 118. CSL Basic Information, Manufacturing Base and Competitors
Table 119. CSL Major Business
Table 120. CSL Vaccine Particulate Adjuvants Product and Services
Table 121. CSL Vaccine Particulate Adjuvants Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 122. CSL Recent Developments/Updates
Table 123. CSL Competitive Strengths & Weaknesses
Table 124. Serum Institute of India Basic Information, Manufacturing Base and Competitors
Table 125. Serum Institute of India Major Business
Table 126. Serum Institute of India Vaccine Particulate Adjuvants Product and Services
Table 127. Serum Institute of India Vaccine Particulate Adjuvants Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 128. Serum Institute of India Recent Developments/Updates
Table 129. Serum Institute of India Competitive Strengths & Weaknesses
Table 130. Bharat Biotech Basic Information, Manufacturing Base and Competitors
Table 131. Bharat Biotech Major Business
Table 132. Bharat Biotech Vaccine Particulate Adjuvants Product and Services
Table 133. Bharat Biotech Vaccine Particulate Adjuvants Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 134. Bharat Biotech Recent Developments/Updates
Table 135. Bharat Biotech Competitive Strengths & Weaknesses
Table 136. Biological E Basic Information, Manufacturing Base and Competitors
Table 137. Biological E Major Business
Table 138. Biological E Vaccine Particulate Adjuvants Product and Services
Table 139. Biological E Vaccine Particulate Adjuvants Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 140. Biological E Recent Developments/Updates
Table 141. Biological E Competitive Strengths & Weaknesses
Table 142. Panacea Biotec Basic Information, Manufacturing Base and Competitors
Table 143. Panacea Biotec Major Business
Table 144. Panacea Biotec Vaccine Particulate Adjuvants Product and Services
Table 145. Panacea Biotec Vaccine Particulate Adjuvants Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 146. Panacea Biotec Recent Developments/Updates
Table 147. Panacea Biotec Competitive Strengths & Weaknesses
Table 148. Valneva Basic Information, Manufacturing Base and Competitors
Table 149. Valneva Major Business
Table 150. Valneva Vaccine Particulate Adjuvants Product and Services
Table 151. Valneva Vaccine Particulate Adjuvants Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 152. Valneva Recent Developments/Updates
Table 153. Valneva Competitive Strengths & Weaknesses
Table 154. SEPPIC Basic Information, Manufacturing Base and Competitors
Table 155. SEPPIC Major Business
Table 156. SEPPIC Vaccine Particulate Adjuvants Product and Services
Table 157. SEPPIC Vaccine Particulate Adjuvants Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 158. SEPPIC Recent Developments/Updates
Table 159. SEPPIC Competitive Strengths & Weaknesses
Table 160. Phibro Animal Health Basic Information, Manufacturing Base and Competitors
Table 161. Phibro Animal Health Major Business
Table 162. Phibro Animal Health Vaccine Particulate Adjuvants Product and Services
Table 163. Phibro Animal Health Vaccine Particulate Adjuvants Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 164. Phibro Animal Health Recent Developments/Updates
Table 165. Phibro Animal Health Competitive Strengths & Weaknesses
Table 166. Aurorium Basic Information, Manufacturing Base and Competitors
Table 167. Aurorium Major Business
Table 168. Aurorium Vaccine Particulate Adjuvants Product and Services
Table 169. Aurorium Vaccine Particulate Adjuvants Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 170. Aurorium Recent Developments/Updates
Table 171. Aurorium Competitive Strengths & Weaknesses
Table 172. Agenus Basic Information, Manufacturing Base and Competitors
Table 173. Agenus Major Business
Table 174. Agenus Vaccine Particulate Adjuvants Product and Services
Table 175. Agenus Vaccine Particulate Adjuvants Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 176. Agenus Recent Developments/Updates
Table 177. Agenus Competitive Strengths & Weaknesses
Table 178. InvivoGen Basic Information, Manufacturing Base and Competitors
Table 179. InvivoGen Major Business
Table 180. InvivoGen Vaccine Particulate Adjuvants Product and Services
Table 181. InvivoGen Vaccine Particulate Adjuvants Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 182. InvivoGen Recent Developments/Updates
Table 183. InvivoGen Competitive Strengths & Weaknesses
Table 184. OZ Biosciences Basic Information, Manufacturing Base and Competitors
Table 185. OZ Biosciences Major Business
Table 186. OZ Biosciences Vaccine Particulate Adjuvants Product and Services
Table 187. OZ Biosciences Vaccine Particulate Adjuvants Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 188. OZ Biosciences Recent Developments/Updates
Table 189. OZ Biosciences Competitive Strengths & Weaknesses
Table 190. Vaxine Basic Information, Manufacturing Base and Competitors
Table 191. Vaxine Major Business
Table 192. Vaxine Vaccine Particulate Adjuvants Product and Services
Table 193. Vaxine Vaccine Particulate Adjuvants Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 194. Vaxine Recent Developments/Updates
Table 195. Vaxine Competitive Strengths & Weaknesses
Table 196. Adjuvatis Basic Information, Manufacturing Base and Competitors
Table 197. Adjuvatis Major Business
Table 198. Adjuvatis Vaccine Particulate Adjuvants Product and Services
Table 199. Adjuvatis Vaccine Particulate Adjuvants Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 200. Adjuvatis Recent Developments/Updates
Table 201. Adjuvatis Competitive Strengths & Weaknesses
Table 202. Desert King Basic Information, Manufacturing Base and Competitors
Table 203. Desert King Major Business
Table 204. Desert King Vaccine Particulate Adjuvants Product and Services
Table 205. Desert King Vaccine Particulate Adjuvants Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 206. Desert King Recent Developments/Updates
Table 207. Desert King Competitive Strengths & Weaknesses
Table 208. Sinovac Basic Information, Manufacturing Base and Competitors
Table 209. Sinovac Major Business
Table 210. Sinovac Vaccine Particulate Adjuvants Product and Services
Table 211. Sinovac Vaccine Particulate Adjuvants Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 212. Sinovac Recent Developments/Updates
Table 213. Sinovac Competitive Strengths & Weaknesses
Table 214. China National Biotec Group Basic Information, Manufacturing Base and Competitors
Table 215. China National Biotec Group Major Business
Table 216. China National Biotec Group Vaccine Particulate Adjuvants Product and Services
Table 217. China National Biotec Group Vaccine Particulate Adjuvants Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 218. China National Biotec Group Recent Developments/Updates
Table 219. China National Biotec Group Competitive Strengths & Weaknesses
Table 220. Walvax Basic Information, Manufacturing Base and Competitors
Table 221. Walvax Major Business
Table 222. Walvax Vaccine Particulate Adjuvants Product and Services
Table 223. Walvax Vaccine Particulate Adjuvants Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 224. Walvax Recent Developments/Updates
Table 225. Walvax Competitive Strengths & Weaknesses
Table 226. Anhui Zhifei Longcom Basic Information, Manufacturing Base and Competitors
Table 227. Anhui Zhifei Longcom Major Business
Table 228. Anhui Zhifei Longcom Vaccine Particulate Adjuvants Product and Services
Table 229. Anhui Zhifei Longcom Vaccine Particulate Adjuvants Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 230. Anhui Zhifei Longcom Recent Developments/Updates
Table 231. Anhui Zhifei Longcom Competitive Strengths & Weaknesses
Table 232. Global Key Players of Vaccine Particulate Adjuvants Upstream (Raw Materials)
Table 233. Global Vaccine Particulate Adjuvants Typical Customers
Table 234. Vaccine Particulate Adjuvants Typical Distributors
Table 1. World Vaccine Particulate Adjuvants Production Value by Region (2021, 2025 and 2032) & (USD Million)
Table 2. World Vaccine Particulate Adjuvants Production Value by Region (2021-2026) & (USD Million)
Table 3. World Vaccine Particulate Adjuvants Production Value by Region (2027-2032) & (USD Million)
Table 4. World Vaccine Particulate Adjuvants Production Value Market Share by Region (2021-2026)
Table 5. World Vaccine Particulate Adjuvants Production Value Market Share by Region (2027-2032)
Table 6. World Vaccine Particulate Adjuvants Production by Region (2021-2026) & (K Units)
Table 7. World Vaccine Particulate Adjuvants Production by Region (2027-2032) & (K Units)
Table 8. World Vaccine Particulate Adjuvants Production Market Share by Region (2021-2026)
Table 9. World Vaccine Particulate Adjuvants Production Market Share by Region (2027-2032)
Table 10. World Vaccine Particulate Adjuvants Average Price by Region (2021-2026) & (US$/Unit)
Table 11. World Vaccine Particulate Adjuvants Average Price by Region (2027-2032) & (US$/Unit)
Table 12. Vaccine Particulate Adjuvants Major Market Trends
Table 13. World Vaccine Particulate Adjuvants Consumption Growth Rate Forecast by Region (2021 & 2025 & 2032) & (K Units)
Table 14. World Vaccine Particulate Adjuvants Consumption by Region (2021-2026) & (K Units)
Table 15. World Vaccine Particulate Adjuvants Consumption Forecast by Region (2027-2032) & (K Units)
Table 16. World Vaccine Particulate Adjuvants Production Value by Manufacturer (2021-2026) & (USD Million)
Table 17. Production Value Market Share of Key Vaccine Particulate Adjuvants Producers in 2025
Table 18. World Vaccine Particulate Adjuvants Production by Manufacturer (2021-2026) & (K Units)
Table 19. Production Market Share of Key Vaccine Particulate Adjuvants Producers in 2025
Table 20. World Vaccine Particulate Adjuvants Average Price by Manufacturer (2021-2026) & (US$/Unit)
Table 21. Global Vaccine Particulate Adjuvants Company Evaluation Quadrant
Table 22. World Vaccine Particulate Adjuvants Industry Rank of Major Manufacturers, Based on Production Value in 2025
Table 23. Head Office and Vaccine Particulate Adjuvants Production Site of Key Manufacturer
Table 24. Vaccine Particulate Adjuvants Market: Company Product Type Footprint
Table 25. Vaccine Particulate Adjuvants Market: Company Product Application Footprint
Table 26. Vaccine Particulate Adjuvants Competitive Factors
Table 27. Vaccine Particulate Adjuvants New Entrant and Capacity Expansion Plans
Table 28. Vaccine Particulate Adjuvants Mergers & Acquisitions Activity
Table 29. United States VS China Vaccine Particulate Adjuvants Production Value Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 30. United States VS China Vaccine Particulate Adjuvants Production Comparison, (2021 & 2025 & 2032) & (K Units)
Table 31. United States VS China Vaccine Particulate Adjuvants Consumption Comparison, (2021 & 2025 & 2032) & (K Units)
Table 32. United States Based Vaccine Particulate Adjuvants Manufacturers, Headquarters and Production Site (States, Country)
Table 33. United States Based Manufacturers Vaccine Particulate Adjuvants Production Value, (2021-2026) & (USD Million)
Table 34. United States Based Manufacturers Vaccine Particulate Adjuvants Production Value Market Share (2021-2026)
Table 35. United States Based Manufacturers Vaccine Particulate Adjuvants Production (2021-2026) & (K Units)
Table 36. United States Based Manufacturers Vaccine Particulate Adjuvants Production Market Share (2021-2026)
Table 37. China Based Vaccine Particulate Adjuvants Manufacturers, Headquarters and Production Site (Province, Country)
Table 38. China Based Manufacturers Vaccine Particulate Adjuvants Production Value, (2021-2026) & (USD Million)
Table 39. China Based Manufacturers Vaccine Particulate Adjuvants Production Value Market Share (2021-2026)
Table 40. China Based Manufacturers Vaccine Particulate Adjuvants Production, (2021-2026) & (K Units)
Table 41. China Based Manufacturers Vaccine Particulate Adjuvants Production Market Share (2021-2026)
Table 42. Rest of World Based Vaccine Particulate Adjuvants Manufacturers, Headquarters and Production Site (State, Country)
Table 43. Rest of World Based Manufacturers Vaccine Particulate Adjuvants Production Value, (2021-2026) & (USD Million)
Table 44. Rest of World Based Manufacturers Vaccine Particulate Adjuvants Production Value Market Share (2021-2026)
Table 45. Rest of World Based Manufacturers Vaccine Particulate Adjuvants Production, (2021-2026) & (K Units)
Table 46. Rest of World Based Manufacturers Vaccine Particulate Adjuvants Production Market Share (2021-2026)
Table 47. World Vaccine Particulate Adjuvants Production Value by Type, (USD Million), 2021 & 2025 & 2032
Table 48. World Vaccine Particulate Adjuvants Production by Type (2021-2026) & (K Units)
Table 49. World Vaccine Particulate Adjuvants Production by Type (2027-2032) & (K Units)
Table 50. World Vaccine Particulate Adjuvants Production Value by Type (2021-2026) & (USD Million)
Table 51. World Vaccine Particulate Adjuvants Production Value by Type (2027-2032) & (USD Million)
Table 52. World Vaccine Particulate Adjuvants Average Price by Type (2021-2026) & (US$/Unit)
Table 53. World Vaccine Particulate Adjuvants Average Price by Type (2027-2032) & (US$/Unit)
Table 54. World Vaccine Particulate Adjuvants Production Value by Particle Architecture, (USD Million), 2021 & 2025 & 2032
Table 55. World Vaccine Particulate Adjuvants Production by Particle Architecture (2021-2026) & (K Units)
Table 56. World Vaccine Particulate Adjuvants Production by Particle Architecture (2027-2032) & (K Units)
Table 57. World Vaccine Particulate Adjuvants Production Value by Particle Architecture (2021-2026) & (USD Million)
Table 58. World Vaccine Particulate Adjuvants Production Value by Particle Architecture (2027-2032) & (USD Million)
Table 59. World Vaccine Particulate Adjuvants Average Price by Particle Architecture (2021-2026) & (US$/Unit)
Table 60. World Vaccine Particulate Adjuvants Average Price by Particle Architecture (2027-2032) & (US$/Unit)
Table 61. World Vaccine Particulate Adjuvants Production Value by Material Composition, (USD Million), 2021 & 2025 & 2032
Table 62. World Vaccine Particulate Adjuvants Production by Material Composition (2021-2026) & (K Units)
Table 63. World Vaccine Particulate Adjuvants Production by Material Composition (2027-2032) & (K Units)
Table 64. World Vaccine Particulate Adjuvants Production Value by Material Composition (2021-2026) & (USD Million)
Table 65. World Vaccine Particulate Adjuvants Production Value by Material Composition (2027-2032) & (USD Million)
Table 66. World Vaccine Particulate Adjuvants Average Price by Material Composition (2021-2026) & (US$/Unit)
Table 67. World Vaccine Particulate Adjuvants Average Price by Material Composition (2027-2032) & (US$/Unit)
Table 68. World Vaccine Particulate Adjuvants Production Value by Antigen Association Mode, (USD Million), 2021 & 2025 & 2032
Table 69. World Vaccine Particulate Adjuvants Production by Antigen Association Mode (2021-2026) & (K Units)
Table 70. World Vaccine Particulate Adjuvants Production by Antigen Association Mode (2027-2032) & (K Units)
Table 71. World Vaccine Particulate Adjuvants Production Value by Antigen Association Mode (2021-2026) & (USD Million)
Table 72. World Vaccine Particulate Adjuvants Production Value by Antigen Association Mode (2027-2032) & (USD Million)
Table 73. World Vaccine Particulate Adjuvants Average Price by Antigen Association Mode (2021-2026) & (US$/Unit)
Table 74. World Vaccine Particulate Adjuvants Average Price by Antigen Association Mode (2027-2032) & (US$/Unit)
Table 75. World Vaccine Particulate Adjuvants Production Value by Application, (USD Million), 2021 & 2025 & 2032
Table 76. World Vaccine Particulate Adjuvants Production by Application (2021-2026) & (K Units)
Table 77. World Vaccine Particulate Adjuvants Production by Application (2027-2032) & (K Units)
Table 78. World Vaccine Particulate Adjuvants Production Value by Application (2021-2026) & (USD Million)
Table 79. World Vaccine Particulate Adjuvants Production Value by Application (2027-2032) & (USD Million)
Table 80. World Vaccine Particulate Adjuvants Average Price by Application (2021-2026) & (US$/Unit)
Table 81. World Vaccine Particulate Adjuvants Average Price by Application (2027-2032) & (US$/Unit)
Table 82. GSK Basic Information, Manufacturing Base and Competitors
Table 83. GSK Major Business
Table 84. GSK Vaccine Particulate Adjuvants Product and Services
Table 85. GSK Vaccine Particulate Adjuvants Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 86. GSK Recent Developments/Updates
Table 87. GSK Competitive Strengths & Weaknesses
Table 88. Merck Basic Information, Manufacturing Base and Competitors
Table 89. Merck Major Business
Table 90. Merck Vaccine Particulate Adjuvants Product and Services
Table 91. Merck Vaccine Particulate Adjuvants Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 92. Merck Recent Developments/Updates
Table 93. Merck Competitive Strengths & Weaknesses
Table 94. Sanofi Basic Information, Manufacturing Base and Competitors
Table 95. Sanofi Major Business
Table 96. Sanofi Vaccine Particulate Adjuvants Product and Services
Table 97. Sanofi Vaccine Particulate Adjuvants Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 98. Sanofi Recent Developments/Updates
Table 99. Sanofi Competitive Strengths & Weaknesses
Table 100. Croda Basic Information, Manufacturing Base and Competitors
Table 101. Croda Major Business
Table 102. Croda Vaccine Particulate Adjuvants Product and Services
Table 103. Croda Vaccine Particulate Adjuvants Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 104. Croda Recent Developments/Updates
Table 105. Croda Competitive Strengths & Weaknesses
Table 106. Novavax Basic Information, Manufacturing Base and Competitors
Table 107. Novavax Major Business
Table 108. Novavax Vaccine Particulate Adjuvants Product and Services
Table 109. Novavax Vaccine Particulate Adjuvants Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 110. Novavax Recent Developments/Updates
Table 111. Novavax Competitive Strengths & Weaknesses
Table 112. SPI Pharma Basic Information, Manufacturing Base and Competitors
Table 113. SPI Pharma Major Business
Table 114. SPI Pharma Vaccine Particulate Adjuvants Product and Services
Table 115. SPI Pharma Vaccine Particulate Adjuvants Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 116. SPI Pharma Recent Developments/Updates
Table 117. SPI Pharma Competitive Strengths & Weaknesses
Table 118. CSL Basic Information, Manufacturing Base and Competitors
Table 119. CSL Major Business
Table 120. CSL Vaccine Particulate Adjuvants Product and Services
Table 121. CSL Vaccine Particulate Adjuvants Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 122. CSL Recent Developments/Updates
Table 123. CSL Competitive Strengths & Weaknesses
Table 124. Serum Institute of India Basic Information, Manufacturing Base and Competitors
Table 125. Serum Institute of India Major Business
Table 126. Serum Institute of India Vaccine Particulate Adjuvants Product and Services
Table 127. Serum Institute of India Vaccine Particulate Adjuvants Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 128. Serum Institute of India Recent Developments/Updates
Table 129. Serum Institute of India Competitive Strengths & Weaknesses
Table 130. Bharat Biotech Basic Information, Manufacturing Base and Competitors
Table 131. Bharat Biotech Major Business
Table 132. Bharat Biotech Vaccine Particulate Adjuvants Product and Services
Table 133. Bharat Biotech Vaccine Particulate Adjuvants Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 134. Bharat Biotech Recent Developments/Updates
Table 135. Bharat Biotech Competitive Strengths & Weaknesses
Table 136. Biological E Basic Information, Manufacturing Base and Competitors
Table 137. Biological E Major Business
Table 138. Biological E Vaccine Particulate Adjuvants Product and Services
Table 139. Biological E Vaccine Particulate Adjuvants Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 140. Biological E Recent Developments/Updates
Table 141. Biological E Competitive Strengths & Weaknesses
Table 142. Panacea Biotec Basic Information, Manufacturing Base and Competitors
Table 143. Panacea Biotec Major Business
Table 144. Panacea Biotec Vaccine Particulate Adjuvants Product and Services
Table 145. Panacea Biotec Vaccine Particulate Adjuvants Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 146. Panacea Biotec Recent Developments/Updates
Table 147. Panacea Biotec Competitive Strengths & Weaknesses
Table 148. Valneva Basic Information, Manufacturing Base and Competitors
Table 149. Valneva Major Business
Table 150. Valneva Vaccine Particulate Adjuvants Product and Services
Table 151. Valneva Vaccine Particulate Adjuvants Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 152. Valneva Recent Developments/Updates
Table 153. Valneva Competitive Strengths & Weaknesses
Table 154. SEPPIC Basic Information, Manufacturing Base and Competitors
Table 155. SEPPIC Major Business
Table 156. SEPPIC Vaccine Particulate Adjuvants Product and Services
Table 157. SEPPIC Vaccine Particulate Adjuvants Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 158. SEPPIC Recent Developments/Updates
Table 159. SEPPIC Competitive Strengths & Weaknesses
Table 160. Phibro Animal Health Basic Information, Manufacturing Base and Competitors
Table 161. Phibro Animal Health Major Business
Table 162. Phibro Animal Health Vaccine Particulate Adjuvants Product and Services
Table 163. Phibro Animal Health Vaccine Particulate Adjuvants Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 164. Phibro Animal Health Recent Developments/Updates
Table 165. Phibro Animal Health Competitive Strengths & Weaknesses
Table 166. Aurorium Basic Information, Manufacturing Base and Competitors
Table 167. Aurorium Major Business
Table 168. Aurorium Vaccine Particulate Adjuvants Product and Services
Table 169. Aurorium Vaccine Particulate Adjuvants Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 170. Aurorium Recent Developments/Updates
Table 171. Aurorium Competitive Strengths & Weaknesses
Table 172. Agenus Basic Information, Manufacturing Base and Competitors
Table 173. Agenus Major Business
Table 174. Agenus Vaccine Particulate Adjuvants Product and Services
Table 175. Agenus Vaccine Particulate Adjuvants Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 176. Agenus Recent Developments/Updates
Table 177. Agenus Competitive Strengths & Weaknesses
Table 178. InvivoGen Basic Information, Manufacturing Base and Competitors
Table 179. InvivoGen Major Business
Table 180. InvivoGen Vaccine Particulate Adjuvants Product and Services
Table 181. InvivoGen Vaccine Particulate Adjuvants Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 182. InvivoGen Recent Developments/Updates
Table 183. InvivoGen Competitive Strengths & Weaknesses
Table 184. OZ Biosciences Basic Information, Manufacturing Base and Competitors
Table 185. OZ Biosciences Major Business
Table 186. OZ Biosciences Vaccine Particulate Adjuvants Product and Services
Table 187. OZ Biosciences Vaccine Particulate Adjuvants Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 188. OZ Biosciences Recent Developments/Updates
Table 189. OZ Biosciences Competitive Strengths & Weaknesses
Table 190. Vaxine Basic Information, Manufacturing Base and Competitors
Table 191. Vaxine Major Business
Table 192. Vaxine Vaccine Particulate Adjuvants Product and Services
Table 193. Vaxine Vaccine Particulate Adjuvants Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 194. Vaxine Recent Developments/Updates
Table 195. Vaxine Competitive Strengths & Weaknesses
Table 196. Adjuvatis Basic Information, Manufacturing Base and Competitors
Table 197. Adjuvatis Major Business
Table 198. Adjuvatis Vaccine Particulate Adjuvants Product and Services
Table 199. Adjuvatis Vaccine Particulate Adjuvants Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 200. Adjuvatis Recent Developments/Updates
Table 201. Adjuvatis Competitive Strengths & Weaknesses
Table 202. Desert King Basic Information, Manufacturing Base and Competitors
Table 203. Desert King Major Business
Table 204. Desert King Vaccine Particulate Adjuvants Product and Services
Table 205. Desert King Vaccine Particulate Adjuvants Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 206. Desert King Recent Developments/Updates
Table 207. Desert King Competitive Strengths & Weaknesses
Table 208. Sinovac Basic Information, Manufacturing Base and Competitors
Table 209. Sinovac Major Business
Table 210. Sinovac Vaccine Particulate Adjuvants Product and Services
Table 211. Sinovac Vaccine Particulate Adjuvants Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 212. Sinovac Recent Developments/Updates
Table 213. Sinovac Competitive Strengths & Weaknesses
Table 214. China National Biotec Group Basic Information, Manufacturing Base and Competitors
Table 215. China National Biotec Group Major Business
Table 216. China National Biotec Group Vaccine Particulate Adjuvants Product and Services
Table 217. China National Biotec Group Vaccine Particulate Adjuvants Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 218. China National Biotec Group Recent Developments/Updates
Table 219. China National Biotec Group Competitive Strengths & Weaknesses
Table 220. Walvax Basic Information, Manufacturing Base and Competitors
Table 221. Walvax Major Business
Table 222. Walvax Vaccine Particulate Adjuvants Product and Services
Table 223. Walvax Vaccine Particulate Adjuvants Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 224. Walvax Recent Developments/Updates
Table 225. Walvax Competitive Strengths & Weaknesses
Table 226. Anhui Zhifei Longcom Basic Information, Manufacturing Base and Competitors
Table 227. Anhui Zhifei Longcom Major Business
Table 228. Anhui Zhifei Longcom Vaccine Particulate Adjuvants Product and Services
Table 229. Anhui Zhifei Longcom Vaccine Particulate Adjuvants Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 230. Anhui Zhifei Longcom Recent Developments/Updates
Table 231. Anhui Zhifei Longcom Competitive Strengths & Weaknesses
Table 232. Global Key Players of Vaccine Particulate Adjuvants Upstream (Raw Materials)
Table 233. Global Vaccine Particulate Adjuvants Typical Customers
Table 234. Vaccine Particulate Adjuvants Typical Distributors
LIST OF FIGURES
Figure 1. Vaccine Particulate Adjuvants Picture
Figure 2. World Vaccine Particulate Adjuvants Production Value: 2021 & 2025 & 2032, (USD Million)
Figure 3. World Vaccine Particulate Adjuvants Production Value and Forecast (2021-2032) & (USD Million)
Figure 4. World Vaccine Particulate Adjuvants Production (2021-2032) & (K Units)
Figure 5. World Vaccine Particulate Adjuvants Average Price (2021-2032) & (US$/Unit)
Figure 6. World Vaccine Particulate Adjuvants Production Value Market Share by Region (2021-2032)
Figure 7. World Vaccine Particulate Adjuvants Production Market Share by Region (2021-2032)
Figure 8. Europe Vaccine Particulate Adjuvants Production (2021-2032) & (K Units)
Figure 9. North America Vaccine Particulate Adjuvants Production (2021-2032) & (K Units)
Figure 10. China Vaccine Particulate Adjuvants Production (2021-2032) & (K Units)
Figure 11. South Korea Vaccine Particulate Adjuvants Production (2021-2032) & (K Units)
Figure 12. India Vaccine Particulate Adjuvants Production (2021-2032) & (K Units)
Figure 13. Australia Vaccine Particulate Adjuvants Production (2021-2032) & (K Units)
Figure 14. Vaccine Particulate Adjuvants Market Drivers
Figure 15. Factors Affecting Demand
Figure 16. World Vaccine Particulate Adjuvants Consumption (2021-2032) & (K Units)
Figure 17. World Vaccine Particulate Adjuvants Consumption Market Share by Region (2021-2032)
Figure 18. United States Vaccine Particulate Adjuvants Consumption (2021-2032) & (K Units)
Figure 19. China Vaccine Particulate Adjuvants Consumption (2021-2032) & (K Units)
Figure 20. Europe Vaccine Particulate Adjuvants Consumption (2021-2032) & (K Units)
Figure 21. Japan Vaccine Particulate Adjuvants Consumption (2021-2032) & (K Units)
Figure 22. South Korea Vaccine Particulate Adjuvants Consumption (2021-2032) & (K Units)
Figure 23. ASEAN Vaccine Particulate Adjuvants Consumption (2021-2032) & (K Units)
Figure 24. India Vaccine Particulate Adjuvants Consumption (2021-2032) & (K Units)
Figure 25. Producer Shipments of Vaccine Particulate Adjuvants by Manufacturer Revenue ($MM) and Market Share (%): 2025
Figure 26. Global Four-firm Concentration Ratios (CR4) for Vaccine Particulate Adjuvants Markets in 2025
Figure 27. Global Four-firm Concentration Ratios (CR8) for Vaccine Particulate Adjuvants Markets in 2025
Figure 28. United States VS China: Vaccine Particulate Adjuvants Production Value Market Share Comparison (2021 & 2025 & 2032)
Figure 29. United States VS China: Vaccine Particulate Adjuvants Production Market Share Comparison (2021 & 2025 & 2032)
Figure 30. United States VS China: Vaccine Particulate Adjuvants Consumption Market Share Comparison (2021 & 2025 & 2032)
Figure 31. United States Based Manufacturers Vaccine Particulate Adjuvants Production Market Share 2025
Figure 32. China Based Manufacturers Vaccine Particulate Adjuvants Production Market Share 2025
Figure 33. Rest of World Based Manufacturers Vaccine Particulate Adjuvants Production Market Share 2025
Figure 34. World Vaccine Particulate Adjuvants Production Value by Type, (USD Million), 2021 & 2025 & 2032
Figure 35. World Vaccine Particulate Adjuvants Production Value Market Share by Type in 2025
Figure 36. Oral
Figure 37. Subcutaneous
Figure 38. Intranasal
Figure 39. Intramuscular
Figure 40. Intradermal
Figure 41. Others
Figure 42. World Vaccine Particulate Adjuvants Production Market Share by Type (2021-2032)
Figure 43. World Vaccine Particulate Adjuvants Production Value Market Share by Type (2021-2032)
Figure 44. World Vaccine Particulate Adjuvants Average Price by Type (2021-2032) & (US$/Unit)
Figure 45. World Vaccine Particulate Adjuvants Production Value by Particle Architecture, (USD Million), 2021 & 2025 & 2032
Figure 46. World Vaccine Particulate Adjuvants Production Value Market Share by Particle Architecture in 2025
Figure 47. Mineral gel / precipitated particles
Figure 48. Liposomal vesicles
Figure 49. Virosomal vesicles
Figure 50. Saponin nanoparticle / ISCOM-type complexes
Figure 51. Polymeric micro- or nanoparticles
Figure 52. Others
Figure 53. World Vaccine Particulate Adjuvants Production Market Share by Particle Architecture (2021-2032)
Figure 54. World Vaccine Particulate Adjuvants Production Value Market Share by Particle Architecture (2021-2032)
Figure 55. World Vaccine Particulate Adjuvants Average Price by Particle Architecture (2021-2032) & (US$/Unit)
Figure 56. World Vaccine Particulate Adjuvants Production Value by Material Composition, (USD Million), 2021 & 2025 & 2032
Figure 57. World Vaccine Particulate Adjuvants Production Value Market Share by Material Composition in 2025
Figure 58. Aluminum salt-based particulate adjuvants
Figure 59. Phospholipid-based particulate adjuvants
Figure 60. Saponin-based particulate adjuvants
Figure 61. Polymer-based particulate adjuvants
Figure 62. Virus-membrane / virosome-based particulate adjuvants
Figure 63. Hybrid particulate systems
Figure 64. Others
Figure 65. Others
Figure 66. World Vaccine Particulate Adjuvants Production Market Share by Material Composition (2021-2032)
Figure 67. World Vaccine Particulate Adjuvants Production Value Market Share by Material Composition (2021-2032)
Figure 68. World Vaccine Particulate Adjuvants Average Price by Material Composition (2021-2032) & (US$/Unit)
Figure 69. World Vaccine Particulate Adjuvants Production Value by Antigen Association Mode, (USD Million), 2021 & 2025 & 2032
Figure 70. World Vaccine Particulate Adjuvants Production Value Market Share by Antigen Association Mode in 2025
Figure 71. Surface-adsorbed particulate systems
Figure 72. Encapsulated particulate systems
Figure 73. Co-assembled particulate systems
Figure 74. Admixture particulate systems
Figure 75. Others
Figure 76. World Vaccine Particulate Adjuvants Production Market Share by Antigen Association Mode (2021-2032)
Figure 77. World Vaccine Particulate Adjuvants Production Value Market Share by Antigen Association Mode (2021-2032)
Figure 78. World Vaccine Particulate Adjuvants Average Price by Antigen Association Mode (2021-2032) & (US$/Unit)
Figure 79. World Vaccine Particulate Adjuvants Production Value by Application, (USD Million), 2021 & 2025 & 2032
Figure 80. World Vaccine Particulate Adjuvants Production Value Market Share by Application in 2025
Figure 81. Infectious Diseases
Figure 82. Cancer
Figure 83. Others
Figure 84. World Vaccine Particulate Adjuvants Production Market Share by Application (2021-2032)
Figure 85. World Vaccine Particulate Adjuvants Production Value Market Share by Application (2021-2032)
Figure 86. World Vaccine Particulate Adjuvants Average Price by Application (2021-2032) & (US$/Unit)
Figure 87. Vaccine Particulate Adjuvants Industry Chain
Figure 88. Vaccine Particulate Adjuvants Procurement Model
Figure 89. Vaccine Particulate Adjuvants Sales Model
Figure 90. Vaccine Particulate Adjuvants Sales Channels, Direct Sales, and Distribution
Figure 91. Methodology
Figure 92. Research Process and Data Source
Figure 1. Vaccine Particulate Adjuvants Picture
Figure 2. World Vaccine Particulate Adjuvants Production Value: 2021 & 2025 & 2032, (USD Million)
Figure 3. World Vaccine Particulate Adjuvants Production Value and Forecast (2021-2032) & (USD Million)
Figure 4. World Vaccine Particulate Adjuvants Production (2021-2032) & (K Units)
Figure 5. World Vaccine Particulate Adjuvants Average Price (2021-2032) & (US$/Unit)
Figure 6. World Vaccine Particulate Adjuvants Production Value Market Share by Region (2021-2032)
Figure 7. World Vaccine Particulate Adjuvants Production Market Share by Region (2021-2032)
Figure 8. Europe Vaccine Particulate Adjuvants Production (2021-2032) & (K Units)
Figure 9. North America Vaccine Particulate Adjuvants Production (2021-2032) & (K Units)
Figure 10. China Vaccine Particulate Adjuvants Production (2021-2032) & (K Units)
Figure 11. South Korea Vaccine Particulate Adjuvants Production (2021-2032) & (K Units)
Figure 12. India Vaccine Particulate Adjuvants Production (2021-2032) & (K Units)
Figure 13. Australia Vaccine Particulate Adjuvants Production (2021-2032) & (K Units)
Figure 14. Vaccine Particulate Adjuvants Market Drivers
Figure 15. Factors Affecting Demand
Figure 16. World Vaccine Particulate Adjuvants Consumption (2021-2032) & (K Units)
Figure 17. World Vaccine Particulate Adjuvants Consumption Market Share by Region (2021-2032)
Figure 18. United States Vaccine Particulate Adjuvants Consumption (2021-2032) & (K Units)
Figure 19. China Vaccine Particulate Adjuvants Consumption (2021-2032) & (K Units)
Figure 20. Europe Vaccine Particulate Adjuvants Consumption (2021-2032) & (K Units)
Figure 21. Japan Vaccine Particulate Adjuvants Consumption (2021-2032) & (K Units)
Figure 22. South Korea Vaccine Particulate Adjuvants Consumption (2021-2032) & (K Units)
Figure 23. ASEAN Vaccine Particulate Adjuvants Consumption (2021-2032) & (K Units)
Figure 24. India Vaccine Particulate Adjuvants Consumption (2021-2032) & (K Units)
Figure 25. Producer Shipments of Vaccine Particulate Adjuvants by Manufacturer Revenue ($MM) and Market Share (%): 2025
Figure 26. Global Four-firm Concentration Ratios (CR4) for Vaccine Particulate Adjuvants Markets in 2025
Figure 27. Global Four-firm Concentration Ratios (CR8) for Vaccine Particulate Adjuvants Markets in 2025
Figure 28. United States VS China: Vaccine Particulate Adjuvants Production Value Market Share Comparison (2021 & 2025 & 2032)
Figure 29. United States VS China: Vaccine Particulate Adjuvants Production Market Share Comparison (2021 & 2025 & 2032)
Figure 30. United States VS China: Vaccine Particulate Adjuvants Consumption Market Share Comparison (2021 & 2025 & 2032)
Figure 31. United States Based Manufacturers Vaccine Particulate Adjuvants Production Market Share 2025
Figure 32. China Based Manufacturers Vaccine Particulate Adjuvants Production Market Share 2025
Figure 33. Rest of World Based Manufacturers Vaccine Particulate Adjuvants Production Market Share 2025
Figure 34. World Vaccine Particulate Adjuvants Production Value by Type, (USD Million), 2021 & 2025 & 2032
Figure 35. World Vaccine Particulate Adjuvants Production Value Market Share by Type in 2025
Figure 36. Oral
Figure 37. Subcutaneous
Figure 38. Intranasal
Figure 39. Intramuscular
Figure 40. Intradermal
Figure 41. Others
Figure 42. World Vaccine Particulate Adjuvants Production Market Share by Type (2021-2032)
Figure 43. World Vaccine Particulate Adjuvants Production Value Market Share by Type (2021-2032)
Figure 44. World Vaccine Particulate Adjuvants Average Price by Type (2021-2032) & (US$/Unit)
Figure 45. World Vaccine Particulate Adjuvants Production Value by Particle Architecture, (USD Million), 2021 & 2025 & 2032
Figure 46. World Vaccine Particulate Adjuvants Production Value Market Share by Particle Architecture in 2025
Figure 47. Mineral gel / precipitated particles
Figure 48. Liposomal vesicles
Figure 49. Virosomal vesicles
Figure 50. Saponin nanoparticle / ISCOM-type complexes
Figure 51. Polymeric micro- or nanoparticles
Figure 52. Others
Figure 53. World Vaccine Particulate Adjuvants Production Market Share by Particle Architecture (2021-2032)
Figure 54. World Vaccine Particulate Adjuvants Production Value Market Share by Particle Architecture (2021-2032)
Figure 55. World Vaccine Particulate Adjuvants Average Price by Particle Architecture (2021-2032) & (US$/Unit)
Figure 56. World Vaccine Particulate Adjuvants Production Value by Material Composition, (USD Million), 2021 & 2025 & 2032
Figure 57. World Vaccine Particulate Adjuvants Production Value Market Share by Material Composition in 2025
Figure 58. Aluminum salt-based particulate adjuvants
Figure 59. Phospholipid-based particulate adjuvants
Figure 60. Saponin-based particulate adjuvants
Figure 61. Polymer-based particulate adjuvants
Figure 62. Virus-membrane / virosome-based particulate adjuvants
Figure 63. Hybrid particulate systems
Figure 64. Others
Figure 65. Others
Figure 66. World Vaccine Particulate Adjuvants Production Market Share by Material Composition (2021-2032)
Figure 67. World Vaccine Particulate Adjuvants Production Value Market Share by Material Composition (2021-2032)
Figure 68. World Vaccine Particulate Adjuvants Average Price by Material Composition (2021-2032) & (US$/Unit)
Figure 69. World Vaccine Particulate Adjuvants Production Value by Antigen Association Mode, (USD Million), 2021 & 2025 & 2032
Figure 70. World Vaccine Particulate Adjuvants Production Value Market Share by Antigen Association Mode in 2025
Figure 71. Surface-adsorbed particulate systems
Figure 72. Encapsulated particulate systems
Figure 73. Co-assembled particulate systems
Figure 74. Admixture particulate systems
Figure 75. Others
Figure 76. World Vaccine Particulate Adjuvants Production Market Share by Antigen Association Mode (2021-2032)
Figure 77. World Vaccine Particulate Adjuvants Production Value Market Share by Antigen Association Mode (2021-2032)
Figure 78. World Vaccine Particulate Adjuvants Average Price by Antigen Association Mode (2021-2032) & (US$/Unit)
Figure 79. World Vaccine Particulate Adjuvants Production Value by Application, (USD Million), 2021 & 2025 & 2032
Figure 80. World Vaccine Particulate Adjuvants Production Value Market Share by Application in 2025
Figure 81. Infectious Diseases
Figure 82. Cancer
Figure 83. Others
Figure 84. World Vaccine Particulate Adjuvants Production Market Share by Application (2021-2032)
Figure 85. World Vaccine Particulate Adjuvants Production Value Market Share by Application (2021-2032)
Figure 86. World Vaccine Particulate Adjuvants Average Price by Application (2021-2032) & (US$/Unit)
Figure 87. Vaccine Particulate Adjuvants Industry Chain
Figure 88. Vaccine Particulate Adjuvants Procurement Model
Figure 89. Vaccine Particulate Adjuvants Sales Model
Figure 90. Vaccine Particulate Adjuvants Sales Channels, Direct Sales, and Distribution
Figure 91. Methodology
Figure 92. Research Process and Data Source
